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 Background: Heart failure patients experience low health-related quality of life and poor 
health outcomes. 
Objective: The purpose of this study was to examine interrelationships among and 
predictors of health-related quality of life of adults with heart failure. 
Methods: This cross-sectional secondary analysis of 161 older (M=56.09 years ± 11.74), 
white (93.2%), male (69.6%) heart failure patients was prescribed angiotensin converting 
enzyme inhibitors and used electronic Medication Event Monitoring System.  Ejection fraction, 
comorbid conditions, vitality, age, gender, income, prescription insurance, social support 
(appraisal, belonging, self-esteem, and tangible support by Interpersonal Support Evaluation 
List), medication regimen (number of prescribed medications and times per day medication is 
prescribed), medication adherence (days adherence and on-time adherence), general health 
perceptions, and health-related quality of life (Short Form-36 physical and mental component 
scores) were analyzed by simple and multiple linear regression. 
Results: Vitality was positively associated with mental (p=<.001) and physical (p=<.001) 
component scores of health-related quality of life.  Females (p=.033) and those with prescription 
insurance (p=.032) had decreased mental component scores, while on-time adherence (p=.043) 
was positively associated with mental component scores.  Greater number of prescribed 
medications (p=.038) was associated with decreased physical component scores, while increased 
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general health perceptions (p<.001) were associated with increased physical component scores.  
More comorbid conditions (p=.024) and increased social support (appraisal, p=.016) were 
associated with decreased vitality, whereas increased social support (self-esteem, p=.035) was 
associated with increased vitality.  Higher income (p=.023) was associated with increased days 
adherence.  Greater number of times per day medication is prescribed (p=.002) was associated 
with decreased on-time adherence, and higher ejection fraction (p=.032) was associated with 
increased on-time adherence.  Vitality (p<.001) was positively associated with general health 
perceptions. 
Conclusions: Interventions that incorporate these variables may reduce negative impacts 
on health-related quality of life and improve health outcomes in heart failure patients. 
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1.0  INTRODUCTION 
Heart failure (HF), a chronic disease in which the heart cannot pump enough blood to meet the 
body’s needs (Hall, Levant, & DeFrances, 2012), affects approximately 5.1 million adult 
Americans with 670,000 new cases per year (Lloyd-Jones et al., 2010).  HF accounted for 
1,106,000 hospitalizations in 2006 and resulted in approximately 281,437 deaths in 2008 (Lloyd-
Jones et al., 2010; Roger et al., 2012).  HF is the most common diagnosis of hospitalized patients 
over 65 years and men (Lloyd-Jones et al., 2010; Roger et al., 2004).  HF accounts for an 
estimated 40% of preventable hospitalizations of adults over 65 years with a cost estimated at 
$32 billion for 2013 (Heidenreich et al., 2011). 
HF management includes medication, diet, fluid management, daily weight monitoring, 
exercise, and rest (Hodges, 2009a).  Medication adherence is imperative for successful 
management and prevention of exacerbations (Hodges, 2009a).  Medication adherence and other 
self-care activities are essential to successful management of HF (Evangelista & Shinnick, 2008).  
However, medication nonadherence and other lifestyle recommendations are a major problem in 
patients with HF (Van der Wal, Jaarsma, & Van Veldhuisen, 2005).  Several factors have been 
identified as having a relationship to medication adherence.  Multiple co-morbidities have been 
linked to nonadherence (Soumerai et al., 2006). Medication nonadherence is a particular issue 
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with older adults (Schlenk, Bernardo, Organist, Klem, & Engberg, 2008) with cost of 
medications identified as a barrier to adherence (Wu, Moser, Chung, Lennie, Peden et al., 2008).  
Furthermore, HF patients often face complex schedules that pose a challenge. 
Health-related quality of life (HRQOL) is low in hospitalized patients with HF (Chin & 
Goldman, 1998).  Biological and physiological factors such as ejection fraction (EF) and 
comorbid conditions influence physical symptom status such as vitality, or energy level, which is 
a predictor of HRQOL (Heo, Doering, Widener, & Moser, 2008).  Older age has been associated 
with increased risk of poorer HRQOL (Gallicchio, Hoffman, & Helzlsouer, 2007).  HF results in 
substantial impairment of HRQOL for both men and women (Gallicchio et al., 2007; Heo, 
Lennie, Okoli, & Moser, 2009; Sayers, Riegel, Pawlowski, Coyne, & Samaha, 2008) with 
HRQOL more impaired in women than men (Gallicchio et al., 2007).  Better income has been 
associated with higher HRQOL (Clark, Tu, Weiner, & Murray, 2003).  Changes in social support 
have been shown to be associated with changes in HRQOL (Bennett, Perkins, Lane, Deer, 
Brater, & Murray, 2001).  Poor adherence may contribute to poorer HRQOL (Hauptman, 2008).  
Medication regimen, particularly number of medications (Demir & Unsar, 2011) and frequency 
of dosing (Dunbar-Jacob, Bohachick, Mortimer, Sereika, & Foley, 2003) affects HRQOL.  Poor 
adherence may contribute to poorer HRQOL (Hauptman, 2008).  General health perceptions 
(GHP) have a direct effect on HRQOL in HF patients (Grady et al., 1995). 
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1.1 PROBLEM OF INTEREST 
The impact of unmanaged HF is comprised of potential or actual disability, loss of independence, 
decreased socialization, financial burden for both the person and the health care system, and 
decreased HRQOL.  HF contributed to 1,801,000 office visits in 2010, and 668,000 emergency 
department visits and 293,000 outpatient visits in 2009 (Go et al., 2013).  HF was listed as the 
first diagnosis for hospital discharges in 1,094,000 cases (Roger et al., 2012).  There is a need to 
study factors that influence HRQOL in the HF population.  The knowledge gained would 
contribute to the development of interventions to improve HRQOL of persons with HF. 
1.2 PURPOSE 
The purpose of the proposed study is to examine interrelationships among and predictors of 
HRQOL of adults with HF utilizing the Wilson and Cleary (1995) model. 
1.3 BROAD LONG-TERM OBJECTIVES 
The long-term goal of this research is to provide health care workers with effective methods of 
identifying those factors influencing HRQOL.  This information will contribute to the 
development of future intervention studies that can lead to improved HRQOL of people with HF.  
Any improvement in HRQOL may decrease HF exacerbations, admissions, and medical costs. 
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1.4 SPECIFIC AIMS 
The specific aims of this study are to examine (1) EF, comorbid conditions, age, gender, income, 
prescription insurance, social support, and medication regimen as predictors of vitality of HF 
clinic patients; (2) EF, comorbid conditions, vitality, age, gender, income, prescription insurance, 
social support, and medication regimen as predictors of adherence to angiotensin converting 
enzyme (ACE) inhibitor medication therapy; (3) EF, comorbid conditions, vitality, age, gender, 
income, prescription insurance, social support, medication regimen, and medication adherence as 
predictors of GHP; and (4) EF, comorbid conditions, vitality, age, gender, income, prescription 
insurance, social support, medication regimen, medication adherence, and GHP as predictors of 
HRQOL. 
1.5 HYPOTHESES 
The specific hypotheses are: 
(1) Biological and physiological factors (EF and comorbid conditions), characteristics of the 
individual (age, gender, income, and prescription insurance) and characteristics of the 
environment (social support [4 variables] and medication regimen [number of prescribed 
medications and number of times per day medication is prescribed]) have a direct effect on 
symptom status (vitality). 
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(2) Biological and physiological factors (EF and comorbid conditions), symptom status (vitality), 
characteristics of the individual (age, gender, income, and prescription insurance) and 
characteristics of the environment (social support [4 variables] and medication regimen [number 
of prescribed medications and number of times per day medication is prescribed]) have a direct 
effect on medication adherence (3 variables); 
(3) Biological and physiological factors (EF and comorbid conditions), symptom status (vitality), 
characteristics of the individual (age, gender, income, and prescription insurance), characteristics 
of the environment (social support [4 variables] and medication regimen [number of prescribed 
medications and number of times per day medication is prescribed]), and medication adherence 
(3 variables) have a direct effect on GHP. 
(4) Biological and physiological factors (EF and comorbid conditions), symptom status (vitality), 
characteristics of the individual (age, gender, income, and prescription insurance), characteristics 
of the environment (social support [4 variables] and medication regimen [number of prescribed 
medications and number of times per day medication is prescribed]), medication adherence (3 
variables), and GHP have a direct effect on HRQOL (2 variables). 
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1.6 BACKGROUND AND SIGNIFICANCE 
1.6.1 Heart Failure 
The hallmark Framingham Heart Study (FHS) enrolled 1,980 men and 2,421 women residing in 
Framingham, Massachusetts, between 1948 and 1951, in this first of its kind study to collect 
information from a community cohort (Mehta & Khan, 2002).  Fifty years worth of data was 
collected and numerous papers were published from this study.  This community cohort 
longitudinal study was the first major cardiovascular study and the first study that included 
women.  This study provided the framework of determining HF risk factors and treatment. 
In 1991, the Studies of Left Ventricular Dysfunction (SOLVD) investigators published 
results indicating the positive effects that ACE inhibitors have on HF (SOLVD Investigators, 
1991).  A total of 2,569 HF subjects were randomly assigned to placebo (n=1284) or enalapril 
(n=1285) groups for an average of over 40 months.  The authors concluded that the addition of 
enalapril, an ACE inhibitor, with current HF treatment, significantly decreased mortality and 
hospitalizations for HF (SOLVD Investigators, 1991).  The benefit of ACE inhibitors has been 
described as the most important advance in HF therapy in recent times (Baker, Konstam, 
Bottorff, & Pitt, 1994).  ACE inhibitors are the gold standard treatment for reducing mortality 
and hospitalizations for HF.  ACE inhibitors are the standard recommended medication for 
treatment of HF.  Both groups were mostly male (placebo group = 79.8% and treatment group = 
80.9%) (SOLVD Investigators, 1991). 
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Between 1979 and 2000, utilizing the Framingham Heart Study criteria, 4,537 patients 
residing in Olmsted County, Minnesota were recruited for this cohort study in which the Mayo 
Clinic and Olmsted Medical Center provided most of the care for this sample.  The medical 
records, which were data based through the Rochester Epidemiology Project, linked through a 
central system maintained by the Mayo Clinic (Roger et al., 2004).  Trends in HF and survival 
were monitored.  Hospitalizations were noted to be common with 83% at least once and 43% at 
least four times among the 1,077 subjects with HF.  Incidence of HF was higher among men than 
women.  Although survival after onset of HF was improved overall, women and older adults had 
less improvement in survival after onset of HF than men and younger adults, respectively (Roger 
et al. 2004). 
The Health, Aging, and Body Composition (Health ABC) study enrolled 2,934 
community-dwelling persons without HF in the Pittsburgh, Pennsylvania and Memphis 
Tennessee areas via a random sample of Medicare beneficiaries.  Baseline data were collected 
between April 1997 and June 1998.  All subjects were to report any hospitalizations and every 6 
months were asked questions regarding cardiovascular-related events.  This study found that men 
were more likely to develop HF than women.  No gender-based differences in risk factors were 
identified.  The authors concluded that incident HF is common in older persons (Kalogeropoulos 
et al., 2009). 
In 1998, hospitals and long-term care facilities were required to participate in the ORYX 
initiative, which was the precursor to core measures (Joint Commission, n.d.).  ORYX is not an 
acronym, but is a fast moving "Gazelle like" animal with long horns.  It represents picking away 
at problems and digging for new ways to improve outcomes, which is at the heart of this 
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initiative.  In 1999, the Joint Commission began gathering information about potential core 
measures.  In 2001, the Joint Commission and Centers for Medicare and Medicaid Services 
(CMS) identified the diagnosis of HF as one of the core measures to integrate performance 
measures with accreditation.  In subsequent years, other initiatives emerged.  Hospitals are 
charged with identifying and providing standard evaluation and interventions for a variety of 
targeted procedures and diagnoses, including HF.  Performance measures of HF include 
discharge instructions, left ventricular function assessment, ACE inhibitor use for left ventricular 
systolic dysfunction, and adult smoking cessation advice/counseling.  The overall goal is to 
ultimately decrease the number of preventable readmissions by effectively treating and educating 
HF patients while they are in the hospital.  Despite this national initiative, there has been no 
significant decrease in HF incidence over the past 20 years (Roger et al., 2004). 
Even with breakthroughs in treatment, HF remains a contributing factor in hospital 
admissions and mortality.  Greater than three fourths of the United States population with HF are 
older than 65 years (Ammar et al., 2007) and represent greater than 80% of inpatients with HF 
(Kalogeropoules et al., 2009).  In 2008, one out of every nine deaths has HF mentioned on the 
death certificate (Roger et al., 2012).  Approximately 50% of people diagnosed with HF will be 
deceased within five years (Levy et al., 2002).  The percentages of death rates after 
hospitalization for HF are concerning at 10.4% for 30 days, 20.0% at one year, and 42.3% at five 
years (Roger et al., 2012).  By 2030, an estimated 9 million people will have HF (Heidenreich et 
al., 2011).  The incidence of HF has not decreased, but survival after onset has increased overall 
(Roger et al., 2004).  Older adults have a higher rate of occurrence for HF and, with the increase 
in the aging population, warrant particular attention for HF management. 
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Factors that influence HF outcomes and exacerbations are comorbid conditions (Naylor 
et al., 2004), age (Roger et al., 2004), economic status (Dunlay, Eveleth, Shah, McNallan, & 
Roger, 2011), social support (Luttik, Jaarsma, Moser, Sanderman, & Van Veldhuisen, 2005), 
medication regimen (Naylor et al., 2004), medication adherence (Hope, Wu, Tu, Young, & 
Murray, 2004; Wu, Moser, Chung, & Lennie, 2008), GHP (Morgan et al., 2006) and HRQOL 
(Chin & Goldman, 1998).  Even with the advancements in management, HF numbers continue to 
rise with poor medication adherence in patients playing a major role (Wu, Moser, Chung, and 
Lennie, 2008). 
1.6.2 Wilson and Cleary Model 
The Wilson and Cleary model is the conceptual model that will be used in this study (Wilson & 
Cleary, 1995).  The model is comprised of five components: biological/physical, symptom status, 
functional status, general health perceptions, and overall HRQOL with characteristics of the 
individual and characteristics of the environment as influencing factors on the model.  Each of 
these five components is proposed to be on a continuum from biological measures to more 
complex and integrated measures, such as GHP.  The model proposes causal relationships with 
HRQOL as the outcome (see Figure 1). 
 
 
 
 
 9 
 
 
  
 
 
 
 
 
Figure 1. Wilson and Cleary Model of Health-related Quality of Life 
 
For this study, the biological/physical component is operationalized as EF and comorbid 
conditions; symptom status is operationalized by a scale of vitality; characteristics of the 
individual include age, gender, income, and prescription insurance; and characteristics of the 
environment include social support and medication regimen.  Functional status assesses the 
ability of the individual to perform particular task and will be operationalized as medication 
adherence.  The general health perceptions component will be operationalized by a scale of GHP.  
HRQOL will be operationalized by scales of mental and physical health. 
Using the Wilson and Cleary model of HRQOL (Wilson & Cleary, 1995), the four 
outcome variables of vitality, medication adherence, GHP and HRQOL will be examined in 
adults with HF.  EF, comorbid conditions, age, gender, income, prescription insurance, social 
support, and medication regimen will be analyzed as predictors of vitality.  EF, comorbid 
conditions, vitality, age, gender, income, prescription insurance, social support, and medication 
regimen will be analyzed as predictors of medication adherence.  EF, comorbid conditions, 
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vitality, age, gender, income, prescription insurance, social support, medication regimen, and 
medication adherence will be analyzed as predictors of GHP.  Lastly, EF, comorbid conditions, 
vitality, age, gender, income, prescription insurance, social support, medication regimen, 
medication adherence, and GHP will be analyzed as predictors of HRQOL (see Figure 2). 
 
 
 
 
 
 
 
 
 
 
Figure 2. Study Model 
1.6.3 Biological and Physiological: EF and Comorbid Conditions 
EF is associated with HF.  It is a measurement of how much blood the left ventricle pumps out 
with each contraction (Hall et al., 2012).  A measurement under 40% may indicate heart failure 
(American Heart Association, 2012).  Comorbid conditions contribute to poor outcomes in 
patients with HF (Naylor et al., 2004).  Comorbidities are prevalent for many older adults with 
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HF and make care challenging because overall treatment includes both HF and the comorbidities 
(Lang & Mancini, 2007). 
1.6.4 Symptom Status: Vitality 
Vitality, often used interchangeably with vigor, is defined as a measurement of energy and the 
absence of fatigue, weakness, and exhaustion (Gump, 1997).  It is common for people with HF to 
experience exercise intolerance and fatigue symptoms (Lewis et al., 2007).  Vitality is viewed as 
a measure of symptom status in relation to the Wilson and Cleary model.  In this model, 
symptom is defined as a patient’s perception of an abnormal physical, emotional, or cognitive 
state (Wilson & Cleary, 1995).  Vitality is measured most often with the Medical Outcomes 
Study Short Form-36 (MOS SF-36) vitality subscale (Gump, 1997). 
1.6.5 Functional Status: Medication Adherence 
Long-term medication adherence is commonly lacking for those with chronic diseases (Dunbar-
Jacob et al., 2003).  There is a major gap between medication that is effective and adherence to 
the prescribed regimen.  Medication adherence is essential to the success of living with HF 
(Evangelista & Shinnick, 2008).  Adherence is a prime factor in positive clinical outcomes in HF 
(Hodges, 2009a).  Medication non-adherence is the primary reason of HF flares and hospital 
readmissions (Chin & Goldman, 1998; Hope et al., 2004).  Poor adherence is also associated 
with increased mortality (Granger et al., 2009).  In 2001, the American College of 
 12 
 
 
Cardiology/American Heart Association established guidelines that all patients with HF should 
be treated with an ACE inhibitor, or angiotensin receptor blocker (ARB) as an alternative, and a 
beta blocker. 
Even with the knowledge of effective treatment, medication adherence is still a challenge.  
Adherence to ACE inhibitor therapy of HF clinic patients who used an electronic event monitor 
for adherence measurement over three months has shown favorable rates in a descriptive 
observational study with mean dose adherence of 94.3% (SD=13.2), mean days adherence of 
84.1% (SD=23.2), and mean on-time adherence of 74.1% (SD=28.6) (Bohachick, Burke, Sereika, 
Murali, & Dunbar-Jacob, 2002).  However, the authors concluded that a large percentage of 
subjects demonstrated adherence problems, particularly with more frequent dosages.  Lower 
adherence is associated with increased cardiovascular-related emergency room visits (Hope et 
al., 2004).  Continued studies are warranted for factors associated with medication adherence. 
1.6.6 General Health Perceptions: GHP 
Health perceptions are low in older patients with HF compared to healthy older adults (Carlson, 
Pozehl, Hertzog, Zimmerman, & Riegel, 2013; Heo, Moser, Lennie, Zambroski, & Chung, 
2007).  Low health perceptions are linked to higher mortality in patients with HF.  Johansson and 
colleagues (2008) studied 412 older HF outpatients with the purpose of evaluating a single 
question as an indicator of HRQOL.  One question about global perceived health was the 
strongest predictor of HRQOL when compared to the different SF-36 domains (Johansson, 
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Brostrom, Dahlstrom, & Alehagen, 2008).  The authors concluded that this item can predict 
HRQOL in older adults with HF. 
1.6.7 Health-related Quality of Life: HRQOL 
In general, patients with HF self-report a low to moderate overall HRQOL (Bennett et al., 2001).  
HRQOL is low in hospitalized patients with HF (Chin & Goldman, 1998).  Numerous factors 
have been studied and identified as factors or potential factors contributing to HRQOL.  The 
Wilson and Cleary model provides an ideal framework to examine factors predicting HRQOL. 
1.6.8 Individual Characteristics: Age, Gender, Income, and Prescription Insurance 
1.6.8.1 Age 
Despite increased survival for all of those with HF, older adults with HF have less improvement 
in survival after onset of HF than younger adults (Roger et al., 2004).  Sensory perception 
decreases as people age.  This factor may play a part in the ability to fully hear and may possibly 
decrease understanding of signs, symptoms, and self-management.  Poor vision may influence 
the ability to visualize the prescription labels, dosing schedules, or pill colors and shapes.  The 
ability to read prescription labels has been related to fewer emergency room visits (Hope et al., 
2004).  Limited physical ability may increase difficulty with opening the pill bottles and 
handling the pills.  HF patients need to know the dose, frequency, and the medication that is 
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prescribed.  Additionally, HF patients should at least be able to read labels, open pill bottles, and 
know their pill colors and shapes (Hope et al., 2004). 
HF is the most common diagnosis of hospitalized patients over 65 years (Kalogeropoulos 
et al., 2009; Lloyd-Jones et al., 2010).  However, there has been a shift in the composition of 
those hospitalized over age 65 years.  Hospitalization rates of those aged 65-74 years and 75-84 
years have decreased from 2000 to 2010, while rates of those 85 years and older have increased.  
Overall, the rate has decreased by 19% from 2000 to 2010 (Hall et al., 2012). 
1.6.8.2 Gender 
Almost half of the population diagnosed with HF are women (Lloyd-Jones et al., 2010), and 
hospitalizations for both males and females are virtually the same (Hall et al., 2012), yet few 
studies are reflective of the gender population mix.  There are physiologic differences in the 
cardiovascular systems of men and women.  Women have smaller hearts and coronary arteries.  
Men are more likely to develop HF even with no established gender risk factor differences 
(Kalogeropoulos et al., 2009).  Survival after initial onset has increased for all of the HF 
population; however, women have less improvement in survival after onset of HF than men 
(Roger et al., 2004).  From 2000 to 2010, the rate of hospitalization has decreased for women 
(Hall et al., 2012). 
The Framingham Heart Study followed community subjects between 1948 and 1988 
examining survival after onset of HF and concluded that there was a better prognosis for women 
despite being diagnosed at a later age than men (Ho, Anderson, Kannel, Grossman, & Levy, 
1993).  This finding was prior to ACE inhibitor utilization becoming part of the standard 
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treatment for HF.  ACE inhibitor use has been shown to decrease mortality.  This finding is in 
alignment with the authors’ additional conclusion that advancements with HF treatment were not 
related to improvements in overall survival (Ho et.al., 1993).  Women with HF tend to be older 
and have higher ejection fractions (Richardson, 2001).  The Framingham Heart Study findings 
from information gathered from 1971 to 1996 concluded that the lifetime risk is 1 in 5 for both 
men and women for developing HF (Lloyd-Jones et al. 2002).  According to the SOLVD 
registry, women have greater readmission rates than men, which is contradictory of other studies 
(SOLVD Investigators, 1991). 
1.6.8.3 Income and prescription insurance 
Older adults with low income are at higher risk for HF.  Researchers completed 5,153 record 
reviews of seniors without HF in the 1990s, grouping them based on level of education and 
income.  Those that lived on less and $25,000 per year were more likely to develop HF.  Those 
with low income and low education were most at risk (American Heart Association, 2011).  This 
situation was the case even if the subjects had Medicare coverage.  The authors suggested that 
subjects with low incomes may not be able to afford the additional costs such as co-pays in 
conjunction with their Medicare coverage. 
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1.6.9 Environmental Characteristics: Social Support and Medication Regimen 
1.6.9.1 Social support 
Social support influences treatment adherence of people with chronic illness (Sayers et al., 
2008).  Due to the physical limitations associated with HF, attendance and participation in 
activities lessens.  Social support is a strong predictor of hospital readmissions and mortality in 
HF patients; in particular, emotional support provided by partners or spouses plays an important 
role in these outcomes (Bean, Gibson, Flattery, Duncan, & Hess, 2009; Luttik et al., 2005).  
Bennett et al. (2001) examined 227 hospitalized patients with HF.  They completed a social 
support survey and the chronic HF questionnaire at baseline and 12 months.  The authors found 
that tangible support, defined as providing concrete aid and assistance (financial, transportation, 
housekeeping, etc.), and positive social interaction, defined as having persons with whom to 
share social activities, both predicted HF admissions.  Social support has been conceptualized 
into subscales and researched.  Tangible support or providing concrete materials for direct aid, 
such as driving to doctor’s appointments, predicted heart failure-related admissions. 
1.6.9.2 Medication regimen 
Older adults with complex therapeutic regimens have been noted to have more difficulty with 
transition from hospital to home (Naylor et al., 2004).  Wu and colleagues (2008) noted that in 
order to achieve better outcomes, medication adherence is extremely important (Wu, Moser, 
Chung, & Lennie, 2008).  The clinician must explore the cause of therapy failures prior to 
increasing doses or changing prescribed medications (Wu, Moser, Lennie, Peden, Chen, & Heo, 
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2008).  Some of these failures could be related to the medication regimen prescribed.  More 
frequent doses have been linked to poorer adherence (Bohachick et al., 2002). 
1.6.10 Biological and Physiological, Individual Characteristics, and Environmental 
Characteristics on Symptom Status 
1.6.10.1 EF and comorbid conditions on vitality 
The literature is limited on EF and comorbid conditions predicting vitality in patients with HF 
(Heo et al., 2008).  However, Lerner and colleagues (1994) studied 1,319 working men and 
women who completed a modified Job Content Questionnaire, a health distress scale, and the 
MOS SF-36 Health Survey to assess job strain and HRQOL in adults (Lerner, Levine, Malspeis, 
& D’Agostino, 1994).  In this study, two thirds of the subjects reported one or more chronic 
conditions.  The higher the number of chronic conditions, the association with all nine of the 
MOS subscales decreased (vitality included).  Heo and colleagues (2008) found that EF and 
comorbid conditions were not predictors of physical symptom status (Heo et al., 2008). 
1.6.10.2 Age, gender, income, and prescription insurance on vitality 
The literature is sparse on age, gender, income, and insurance predicting vitality in HF patients.  
Heo and colleagues (2008) found that age was an important predictor of physical symptom 
status.  The older population has demonstrated more difficulty in detecting and interpreting 
shortness of breath than younger patients (Riegel et al., 2010).  However, gender was not related 
to or predictive of physical symptoms status (Heo et al., 2008).  Employment status has been 
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found to be an important predictor of physical symptom status for HF patients (Heo et al., 2008).  
There is evidence that having private health insurance and being female decreases hospital 
readmissions for HF (Betihavas et al., 2012).  Employment status has been found to be an 
important predictor of physical symptom status for HF patients (Heo et al., 2008). 
1.6.10.3 Social support and medication regimen on vitality 
Cene and colleagues (2011) found that social isolation is an independent risk factor for HF and is 
strongly mediated by vital exhaustion (Cene et al., 2011).  Nonadherence with the prescribed 
regimen can result in worsening symptoms (Van Der Wal et al., 2005).  Older adults with HF 
who take fewer than six medications are more likely to recover from exhaustion (perception of 
inadequate energy) than those who take multiple medications (Whitson et al., 2011). 
1.6.11 Biological and Physiological, Symptom Status, Individual Characteristics, and 
Environmental Characteristics on Functional Status 
1.6.11.1 EF and comorbid conditions on medication adherence 
Comorbid conditions have been linked to medication adherence.  Soumerai and colleagues 
(2006) examined measures of skipping or reducing doses or not filling prescriptions from a 
national sample of 13,835 Medicare beneficiaries.  The authors reported that all groups 
(nonelderly, elderly, and disabled) reported high rates of medication nonadherence due to cost.  
The authors concluded that cost-related medication nonadherence was further enhanced by poor 
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health, multiple comorbid conditions, and limited prescription drug coverage (Soumerai et al., 
2006). 
1.6.11.2 Vitality on medication adherence 
Vitality has been linked to medication adherence in adults with HF.  Riegel and colleagues 
(2012) followed 202 adults with HF for 6 months from the Northeastern United States.  
Nonadherence dimension indicators (socioeconomic, condition, therapy, patient, and healthcare 
system) identified from the World Health Organization were used to identify predictors of 
nonadherence.  Those with excessive daytime sleepiness, a proxy for vitality, over time had less 
adherence (Riegel et al., 2012).  Recognition of symptoms, particularly shortness of breath, has 
been shown to be more challenging in older adults, which leads to poor self-care management 
(Riegel et al., 2010). 
1.6.11.3 Age, gender, income, and prescription insurance on medication adherence 
There is no clear support of one single intervention to optimize medication adherence in older 
adults (Schlenk et al., 2008).  There are potential influencing factors that may guide health care 
professionals to the appropriate interventions.  Increased age has not been related to adherence, 
but women less than 75 years were found to be less adherent in the CHARM study (Granger et 
al., 2009).  For HF patients, nonadherence rates are high among all ages, ethnic groups, and 
levels of socioeconomic status (Evangelista & Shinnick, 2008). 
Findings are mixed for the relationship between gender and medication adherence.  A 
study of 134 subjects with HF examining predictors of medication adherence utilizing the 
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Medication Event Monitoring System (MEMS), an electronic medication cap used to assess 
medication adherence, concluded that there were no differences in gender regarding medication 
adherence (Wu, Moser, Chung, and Lennie, 2008).  Women generally live longer than men, 
which can lead to living alone.  Women are likely to be socially isolated and have adherence 
problems with prescribed treatment regimens (Albert, 2005). 
Cost of medication with challenges to make ends meet has been identified as a barrier to 
and predictor of medication adherence (Dunlay et al., 2011; Wu, Moser, Chung, & Lennie, 
2008).  Dunbar-Jacob and colleagues (2003) studied 169 older adults with cardiovascular 
comorbid conditions, including HF, and their medication adherence via the MEMS.  In those 
patients with HF, income predicted lower medication adherence for both percentage of days with 
correct number of doses taken and percentage of expected doses within the correct timing 
interval (Dunbar-Jacob et al., 2003).  Additionally, prescription insurance did not predict 
adherence (Dunbar-Jacob et al., 2003). 
The more restrictive the prescription coverage plan is, the greater the risk of decreased 
medication adherence (Thanassoulis et al., 2009).  Inadequate prescription coverage may be a 
factor in adherence problems for chronically ill adults (Hsu, 2006; Piette, Heisler, & Wagner, 
2004; Soumarai et al., 2006). 
1.6.11.4 Social support and medication regimen on medication adherence 
Social support is one of the major predictors of adherence.  HF patients who are depressed or 
lack social support have increased morbidity and hospital readmissions, are less adherent to their 
medical regimen, and have an overall increase in cost of care (Richardson, 2003).  Patients who 
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perceived adequate social support from family members or others are more adherent (Sayers et 
al., 2008; Wu, Moser, Chung, and Lennie, 2008).  Perceived social support has been moderately 
associated with better self-reported medication adherence, dietary adherence, and other self-care 
activities including daily weighing (Sayers et al., 2008); more specifically, emotional support has 
been related to medication adherence (Sayers et al., 2008). 
Multiple and complex medications and schedules contribute to the difficulty with 
adherence in older adults with HF.  Inconvenient scheduling, frequent dosing and number of 
medications are all identified as barriers to medication adherence (Bohachick et al., 2002; Wu, 
Moser, Lennie, Peden, Chen, and Heo, 2008).  Both the number of medications and frequency of 
dosing affect medication adherence (Dunbar-Jacob et al., 2003).  Riegel and colleagues (2012) 
studied predictors of adherence in HF patients.  They found that patients who had greater than 2 
medication dosings per day had less adherence (Riegel et al., 2012).  Conversely, Wu, Moser, 
Chung, and Lennie (2008) found that number of pills taken per day and number of times per day 
medication is prescribed are not related to medication adherence. 
1.6.12 Biological and Physiological, Symptom Status, Individual Characteristics, 
Environmental Characteristics, and Functional Status on GHP 
1.6.12.1 EF and comorbid conditions on GHP 
Consistent with other studies of EF on components of HRQOL, EF is not associated with any 
HRQOL subscale (Clark et al., 2003; Krethong, Jirapaet, Jitpanya, & Sloan, 2008), including 
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GHP.  Comorbid conditions have been found to be associated with decreased GHP (Carlson et 
al., 2013; Suwanno, Petpichetchian, Riegel, & Issaramalai, 2009). 
1.6.12.2 Vitality on GHP 
Perceived health competence has been associated with symptoms of dyspnea and GHP in 
patients with HF (Arnold et al., 2005).  Furthermore, a change in symptoms has been linked to 
decreased overall perceived health (Carlson et al., 2013).  A causal study of Thai HF patients 
found that symptom status has a direct effect on GHP (Krethong et al., 2008). 
1.6.12.3 Age, gender, income and prescription insurance on GHP 
Increased age has had mixed results in the literature on GHP.  In a study of perceived overall 
health, 212 older patients participated in a seven-month medication adherence study.  The study 
concluded that increased age was related to an increase in GHP (Clark et al., 2003).  However, 
Suwanno and colleagues (2009) concluded that increased age had a direct negative effect on 
health status (Suwanno et al., 2009).  Women have a higher reported health perception than men 
(Evangelista et al., 2001).  Additionally, being female is also identified with decreased 
hospitalizations (Betihavas et al., 2012).  Low income, non-white, male patients with HF report a 
poor health perception (Macabasco-O’Connell, Crawford, Stotts, Stewart, & Froelicher, 2009).  
Further, perceived sufficiency of income has predicted overall perceived health (Carlson et al., 
2013). 
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1.6.12.4 Social support and medication regimen on GHP 
Psychosocial function and breathlessness/physical function directly affect global perceived 
health (Johansson et al., 2007).  In Thai HF patients, social support had a significant positive 
direct effect on GHP (Krethong et al., 2008).  The need to manage multiple medical prescriptive 
therapies is associated with decreased overall perception of health (Carlson et al., 2013). 
1.6.12.5 Medication adherence on GHP 
Krethong and colleagues (2008) studied 422 HF patients who visited clinics across Thailand.  
The researchers collected medical record data and administered questionnaires.  Patients who 
rated their functional status as low in turn rated their GHP as low (Krethong et al., 2008). 
1.6.13 Biological and Physiological, Symptom Status, Individual Characteristics, 
Environmental Characteristics, Functional Status, and GHP on HRQOL 
1.6.13.1 EF and comorbid conditions on HRQOL 
Juenger and colleagues (2002) studied HRQOL using the SF-36 in 205 German patients with HF 
and compared them with patients with other chronic diseases.  The findings revealed that EF did 
not influence HRQOL.  The study was limited by the small sample size and the sample was not 
representative of the HF population.  The study concluded that other predictors of HRQOL 
should be explored and future studies with larger more representative samples are needed 
(Juenger et al., 2002).  Heo and colleagues (2008) also found that EF was not predictive of 
HRQOL.  They followed 84 patients with HF exacerbations after being discharged from four 
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hospitals in Columbus, Ohio and Lexington, Kentucky.  The researchers administered the 
Minnesota Living with Heart Failure (MLHF) questionnaire and Dyspnea-Fatigue Index three 
months post-discharge to measure HRQOL and symptoms status, respectively (Heo et al., 2008).  
Clark and colleagues (2003) also concluded that both EF and comorbid conditions did not 
influence HRQOL in subjects with HF (Clark et al., 2003). 
However, Lewis and colleagues (2007) studied HRQOL in 2,709 subjects from the 
CHARM program with both preserved and low EF.  Subjects were enrolled from 243 sites in the 
United States and Canada.  Both groups equally reported low HRQOL via the MLHF 
questionnaire.  The authors concluded that further evaluation of factors affecting HRQOL is 
warranted (Lewis et al., 2007). 
Fewer comorbidities have been associated with increased HRQOL.  Seto and colleagues 
(2011) recruited 100 outpatients from the University Health Network Heart Function Clinic to 
complete the Self-care of HF Index (SCHFI) and the MLHF questionnaire to measure self-care 
behavior and HRQOL, respectively.  The team found that fewer comorbidities were significantly 
related to better emotional quality of life (Seto et al., 2011).  The study was limited by 37% of 
the participants having only been participating in the clinic for less than 6 months.  One third of 
the subjects were called to remind them to complete and return the questionnaires, which may 
have introduced bias. 
1.6.13.2 Vitality on HRQOL 
Heo and colleagues (2008) followed 84 patients with HF exacerbations after being discharged 
from four hospitals in Columbus, Ohio and Lexington, Kentucky.  The researchers administered 
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the MLHF questionnaire and Dyspnea-Fatigue Index three months post-discharge to measure 
HRQOL and symptoms status, respectively.  The authors concluded that better physical 
symptom status was related to better HRQOL (Heo et al., 2008).  The authors concluded that the 
study was limited by its small sample size and recommended futures studies with a larger sample 
size and including an additional variable of adherence to treatment regimen (Heo et al., 2008). 
Recurring symptoms have been linked to decreased HRQOL (Evangelista et al., 2001). 
1.6.13.3 Age, gender, income, and prescription insurance on HRQOL 
HRQOL is related to hospital readmissions in older patients with HF (Hodges, 2009a).  HF 
potentially affects financial status secondary to job loss or increase in medical expenses.  This 
financial burden is viewed negatively in respect to the HRQOL of older adults (Heo et al., 2009).  
Older age has been associated with higher risk for lower HRQOL (Gallicchio et al., 2007).  
Azevedo and colleagues (2008) studied 424 adults greater than 45 years with HF using the SF-36 
and found that increased age was associated with decreased HRQOL, and increased 
socioeconomic status was related positively to HRQOL (Azevedo et al., 2008). 
HF patients report substantial impairment of HRQOL for both men and women 
(Gallicchio et al., 2007; Heo et al., 2009; Sayers et al., 2008), but women to a greater extent 
(Bennett et al., 2001; Gallicchio et al., 2007).  Using the MOS SF-36 as a measure of HRQOL, 
women have less improvement in the physical component score than men at one year (Chin & 
Goldman, 1998).  In a large community-based cohort study in Washington County, Maryland 
known as CLUE-II, 4,498 men and 6,948 women were studied in order to identify factors 
associated with HRQOL.  Investigators sent a follow-up questionnaire inquiring about social 
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support and HRQOL.  The HRQOL question simply asked generally how the subject would rate 
his/her health.  Similar to results by Chin and Goldman (1998), men reported a higher HRQOL 
than women (Gallicchio et al., 2007). 
Income and HRQOL in the HF population has been linked.  Clark and colleagues (2003) 
studied 212 older adults with HF utilizing baseline interview, medical records review, and 
questionnaires (Kansas City Cardiomyopathy, Chronic Heart Failure, and a single question of 
perceived overall health).  Subjects with greater income had higher HRQOL scores (Clark et al., 
2003).  Azevedo and colleagues (2008) found that increased socioeconomic status was related 
positively to HRQOL (Azevedo et al., 2008).  Although the literature is lacking with 
relationships of insurance to HRQOL, insurance is often coupled with income as ability to afford 
the prescribed regimen for optimum outcomes. 
1.6.13.4 Social support and medication regimen on HRQOL 
There is limited research on social support and its impact on outcomes in those persons with HF 
(Luttik et al., 2005).  Physical impairment, polypharmacy, and decreased social support influence 
medication adherence and HRQOL in the older population (Evangelista & Shinnick, 2008; 
Gallicchio et al., 2007; Hope et al., 2004; Luttik et al., 2005; Schlenk et al., 2008).  Social 
support has been positively correlated with HRQOL for both men and women (Gallicchio et al., 
2007).  Changes in social support have been linked to changes in HRQOL in one study.  Bennett 
et al (2001) found that increased social support over a 12-month period predicted positive 
changes in HRQOL and decreased hospitalizations.  Bennett et al. investigated 227 hospitalized 
men and women with HF who were categorized into under and over 65 years of age and 
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completed social support and HF surveys at baseline (n = 227) and 12 months (n = 147).  
Changes in social support were concluded to be predictors of changes in HRQOL.  The authors 
suggested that interventions aimed at those with low social support may improve HRQOL. 
Scant research has been done on the relationship between medication regimen and 
HRQOL.  Number of medications prescribed is associated with HRQOL.  As number of 
medications prescribed increases, HRQOL decreases (Demir & Unsar, 2011). 
1.6.13.5 Medication adherence on HRQOL 
Hospital readmissions for HF are commonly related to medical factors (hypertension), 
environmental factors (decreased social support), and behavioral factors, such as nonadherence 
with medications (Hodges, 2009b).  Hodges studied 41 older adults with HF in San Antonio, 
Texas.  This was a mixed methods study designed to examine individual perceptions in a 
HRQOL framework.  The subjects participated in interviews and completed questionnaires.  
There was a positive relationship between HRQOL and readmissions (Hodges, 2009b), which 
may be partially attributable to medication nonadherence.  Poor adherence may be a contributing 
factor to poorer HRQOL (Hauptman, 2008). 
1.6.13.6 GHP on HRQOL 
Health perceptions have a strong association with HRQOL.  Heo and colleagues (2005) studied 
records from 293 HF patients who were given the MLHF questionnaire.  Health perception and 
symptom status were determined to be most associated with HRQOL (Heo, Moser, Riegel, Hall, 
& Christman, 2005. 
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1.6.14 Gaps 
HF remains an extreme burden on the population as a whole (Roger et al., 2004).  Older adults 
lag behind in improvements in survival after the onset of HF compared to younger adults, which 
indicates that a better understanding is needed to develop effective interventions tailored to 
increasing those factors that have a positive impact on HRQOL of older adults.  The biological 
and physiological factors, EF, and comorbid conditions warrant further study with definition of 
the number of comorbidities and high versus low EF.  Evidence is limited on factors influencing 
vitality and is lacking regarding the effects of specific variables of income, insurance, social 
support, and medication regimen on vitality.  Analysis of the gender differences in factors that 
affect HRQOL are lacking in the literature.  Economic factors (income and insurance) need 
further analysis as predictors of HRQOL.  Social support has had varying degrees of meaning in 
the literature, so there is a need to clearly define and study the relationship of social support 
measures with the outcome of HRQOL.  Medication regimen needs to be further explored to 
determine threshold and directional relationships with HRQOL.  Given the lack of medication 
adherence in a large portion of the HF population, there is continued need for research on ways 
to improve medication adherence, which in turn may affect HRQOL. 
Research should utilize all of the components and influencing factors of the Wilson and 
Cleary model and incorporate all of the variables identified above to contribute to a more 
complete understanding of the complexities and factors contributing to HRQOL in HF patients.  
Efforts to improve HRQOL could decrease hospitalizations.  Interventions with even a small 
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effect on hospital admissions could have a significant effect on the burden of cost on the 
treatment of HF (Lee, Chavez, Baker, & Luce, 2004). 
1.6.15 Importance of Proposed Research 
Part of the solution to this problem is already figured out.  Proper self-care management and 
effective medications (primarily ACE inhibitors) significantly decrease mortality and hospital 
readmissions.  Additionally, better HRQOL is associated with better health outcomes.  However, 
the rest of the puzzle has not been successfully figured out.  That is, how do health care 
professionals give HF patients the knowledge, tools, and confidence to follow the successfully 
discovered regimen to decrease exacerbations, thus lessening readmission and optimizing their 
HRQOL?  With HRQOL primarily low in patient with HF, which is associated with poor health 
outcomes, research on the factors affecting HRQOL will guide clinicians about where to focus 
improvement interventions.  Further insight into those factors that influence HRQOL will aid in 
the development of those interventions.  In summary, it is important to examine the associations 
that EF, comorbid conditions, vitality, age, gender, income, prescription insurance, social 
support, medication regimen, medication adherence, and GHP have on HRQOL to shed some 
light on development and testing of effective interventions to improve HRQOL. 
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1.7 RESEARCH DESIGN AND METHODS 
The purpose of the proposed study is to examine interrelationships among and predictors of 
HRQOL of adults with HF utilizing the Wilson and Cleary model. 
The specific aims of this study are to examine: 
(1) EF, comorbid conditions, age, gender, income, prescription insurance, social support, and 
medication regimen as predictors of vitality of HF clinic patients; 
(2) EF, comorbid conditions, vitality, age, gender, income, prescription insurance, social support, 
and medication regimen as predictors of adherence to ACE inhibitor medication therapy; 
(3) EF, comorbid conditions, vitality, age, gender, income, prescription insurance, social support, 
medication regimen, and medication adherence as predictors of GHP; and 
(4) EF, comorbid conditions, vitality, age, gender, income, prescription insurance, social support, 
medication regimen, medication adherence, and GHP as predictors of HRQOL. 
1.7.1 Hypotheses 
1.7.1.1 Hypotheses for Aim 1 
(H1.1) Biological and physiological factors (low EF and high comorbid conditions) have a direct 
association with decreased symptom status (vitality). 
(H1.2) Characteristics of the individual (increased age, female, low income, and no prescription 
insurance) have a direct association with decreased symptom status (vitality). 
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(H1.3) Characteristics of the environment (increased social support [4 variables] and less 
complex medication regimen [2 variables]) have a direct association with increased symptom 
status (vitality). 
1.7.1.2 Hypotheses for Aim 2 
(H2.1) Biological and physiological factors (low EF and increased comorbid conditions) have a 
direct association with decreased medication adherence (3 variables). 
(H2.2) Increased symptom status (vitality) has a direct association with increased medication 
adherence (3 variables). 
(H2.3) Characteristics of the individual (increased age, female, low income, and no prescription 
insurance) have a direct association with decreased medication adherence (3 variables). 
(H2.4) Characteristics of the environment (increased social support [4 variables] and less 
complex medication regimen [2 variables]) have a direct association with increased medication 
adherence (3 variables). 
1.7.1.3 Hypotheses for Aim 3 
(H3.1) Biological and physiological factors (low EF and increased comorbid conditions) have a 
direct association with decreased GHP. 
(H3.2) Increased symptom status (vitality) has a direct association with increased GHP. 
(H3.3) Characteristics of the individual (increased age, female, low income, and no prescription 
insurance) have a direct association with decreased GHP. 
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(H3.4) Functional status (increased medication adherence [3 variables]) has a direct association 
with increased GHP. 
(H3.5) Characteristics of the environment (increased social support [4 variables] and less 
complex medication regimen [2 variables]) have a direct association with increased GHP. 
1.7.1.4 Hypotheses for Aim 4 
(H4.1) Biological and physiological factors (low EF and higher comorbid conditions) have a 
direct association with decreased HRQOL (2 variables). 
(H4.2) Increased symptom status (vitality) has a direct association with increased HRQOL (2 
variables). 
(H4.3) Characteristics of the individual (increased age, female, low income, and no prescription 
insurance) have a direct association with decreased HRQOL (2 variables). 
(H4.4) Functional status (increased medication adherence [3 variables]) has a direct association 
with increased HRQOL (2 variables). 
(H4.5) Characteristics of the environment (increased social support [4 variables] and less 
complex medication regimen [2 variables]) have a direct association with increased HRQOL (2 
variables). 
(H4.6) Increased GHP has a direct association with increased HRQOL (2 variables). 
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1.7.2 Research Design 
This proposed study is a secondary analysis of cross-sectional data from the parent study, 
“Medication Adherence and Quality of Life in Chronic Illness” (NIH, National Institute of 
Nursing Research Grant K01 NR00083, Principal Investigator: Patricia Bohachick).  This study 
will use a descriptive correlational design to test the hypotheses.  See Appendix A for a copy of 
the parent study consent document. 
1.7.3 Setting 
The setting in the parent study was a university-affiliated HF clinic.  HF management 
cardiologists and advance practice nurses operate the HF clinic.  Consistency of follow-up visits 
with the same cardiologist occurred.  Frequency of the patient visits was patient condition 
specific.  Outpatients spent approximately 30 minutes with the cardiologist and then additional 
time with the nurse or dietitian as needed for education and counseling.  The clinic was 
associated with the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, an 
internationally recognized academic medical center providing comprehensive medical care, 
education of health care professionals, and research. 
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1.7.4 Population 
The population in the parent study consisted of patients who attended the University of 
Pittsburgh Medical Center Heart Failure clinic in Pittsburgh, Pennsylvania.  This clinic sees 
thousands of persons diagnosed with HF each year supporting the tri-state area of Western 
Pennsylvania, Eastern Ohio, and the Northern Panhandle of West Virginia. 
1.7.5 Sampling Procedures 
The parent study sample was obtained through convenience sampling.  The parent study sample 
was comprised of university-affiliated HF clinic patients who were prescribed ACE inhibitors 
and used electronic event medication monitoring by MEMS over three months to evaluate 
adherence to ACE inhibitor therapy (Bohachick et al., 2002).  Participants had to be 21 years of 
age or older, prescribed ACE inhibitor therapy, and able to self-manage their medications.  
Subjects were excluded from the study if they had an unstable medical condition, exhibited signs 
of confusion, or were unable to read and write English. 
1.7.6 Sample 
The initial sample in the parent study consisted of 235 subjects.  Sixty-four (27.2%) of those 
subjects used dose organizers where they removed multiple pills from the bottle with the MEMS 
cap and placed them into dose organizers from which to administer their medication.  Since the 
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parent study depended on the valid assessment of medication adherence, these 64 subjects were 
excluded from the final sample in the parent study.  Thus, the final parent study sample was 
comprised of the 171 subjects who took their medication directly from the bottle with the MEMS 
cap and completed the Interpersonal Support Evaluation List (ISEL), MOS SF-36, and a 
demographics questionnaire.  Data on 10 of the subjects in the final parent study sample had 
missing values on variables examined in this study (one subject for number of times per day 
medication is prescribed, seven subjects for income, and two subjects for prescription insurance 
coverage).  A missing values analysis demonstrated no variables with 5% or more missing 
values.  Thus, the subjects with missing data were excluded from this study.  The sample for this 
study will be comprised of 161 HF clinic patients with complete data on the proposed study 
variables. 
1.7.7 Instruments 
1.7.7.1 Demographics questionnaire 
The Demographics questionnaire is a self-report questionnaire completed by subjects that 
provides socio-demographic data such as age, gender, marital status, race, education level, 
employment status, occupation, income, and questions about medication insurance coverage, 
cost, and regimen (See Appendix B).  Data will be pulled from the Demographics questionnaire 
to describe the sample.  Age, gender, income, and insurance data obtained from this 
questionnaire will be considered characteristics of the individual in the Wilson and Cleary 
model. 
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1.7.7.2 Medical Record Data (MRD)   
Medical information was gathered from the subject’s medical record and recorded onto the MRD 
(See Appendix B).  EF and comorbid conditions from the MRD will be considered biological 
and physiological factors in the Wilson and Cleary model.  Number of medications and number 
of times per day medication is prescribed from the MRD are elements of the medication regimen 
and will be considered environmental characteristics in the Wilson and Cleary model. 
1.7.7.3 Interpersonal Support Evaluation List (ISEL)   
The ISEL, a 40-item self-report measure, will be used to measure social support (See Appendix 
B).  The ISEL is based on the premise that social resources potentially aide with coping in 
stressful situations.  The ISEL, used to measure the perceived availability of potential social 
support resources, contains four subscales:  appraisal support, sense of belonging support, self-
esteem support, and tangible support.  Appraisal support is one’s perceived availability to talk 
about one’s problems.  Belonging support is the perceived availability of someone with whom 
one can do things.  Self-esteem support is the perceived availability of a positive comparison of 
one’s self with others.  Tangible support is perceived availability of material aid (Cohen, 
Mermelstrin, Kamarck, & Hoberman, 1985).  The scores from the ISEL are highly ordinal and 
approximate interval scaled variables.  Half (20 items) of the items are constructed positively and 
half (20 items) negatively.  Items are rated on a 4-point scale with response to statement choices 
of definitely false, probably false, probably true, or definitely true.  Each statement has a scoring 
range of 0 - 3 with a potential range of 0 - 120 for the total score.  The higher the score, the 
greater the perceived social support is viewed.  The subscale scores are obtained similarly with a 
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range from 0 - 30 with higher scores meaning greater perceived social support (Cohen et al., 
1985). 
The ISEL is a widely used, valid and reliable instrument.  The general population scale 
correlated at 0.30 with the established Moos Family Environment Scale and 0.31 with the Partner 
Adjustment Scale (Cohen et al., 1985).  Cohen et al. (1985) reported that internal consistency 
reliability in the general population was favorable with alpha coefficient ranges for the total 
ISEL from 0.88 to 0.90.  Reports of the subscales were 0.70 to 0.82 for appraisal support, 0.73 to 
0.78 for belonging support, 0.62 to 0.73 for self-esteem support, and 0.73 to 0.81 for tangible 
support. 
Test-retest reliability was reported for two days, six weeks, and six months in the general 
population from data obtained from five studies.  Reliability estimates ranged from 0.70 to 0.87 
for the total ISEL, 0.60 to 0.84 for appraisal support, 0.65 to 0.68 for belonging support, 0.54 to 
0.74 for self-esteem support, and 0.49 to 0.78 for tangible support (Cohen et al., 1985). 
The general population ISEL was administered three times in the Oregon Smoking Study 
(community sample) at baseline, six weeks, and six months.  Mean scores ranged from 32.9 to 
34.4.  Standard deviations ranged from 4.96 to 5.98.  In this analysis, social support will be 
viewed as a characteristic of the environment in the Wilson and Cleary model. 
1.7.7.4 Medication Event Monitoring System (MEMS)   
Medication adherence was measured by electronic event monitoring using MEMS.  This method 
provides an alternate more objective method than the self-report method of medication 
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adherence.  Data are electronically gathered and stored in the cap of the pill bottle that can later 
be downloaded for analysis of medication taking practices. 
The MEMS recorded the date and time the bottle was opened.  From these serially 
collected data, summary indices were derived that provided global measures of medication 
adherence that are continuous, ratio scaled variables.  The three measures of medication 
adherence are:  percentage of prescribed administrations taken (dose adherence), percentage of 
days with the prescribed number of administrations (days adherence), and percentage of days 
with the prescribed number of administrations and optimal inter-dose intervals (on-time 
adherence).  Optimal inter-dose intervals were computed as the time interval between bottle 
openings and were within 25% of the optimal dosing interval.  For example, for once daily 
dosing, 24 ± 6 hours of the previous bottle opening is optimum; for twice daily dosing, 12 ± 3 
hours of the previous bottle opening is optimum; and for three times per day dosing, 8 ± 2 hours 
of the previous bottle opening is optimum. 
Obtaining adherence data electronically, such as through the MEMS, reveals adherence 
information that may not otherwise be obtained through alternate means such as via diary 
submission.  MEMS provides an objective accuracy that is lacking with the self-report methods.  
The AARDEX Group (n.d.) that manufactures the MEMS product used in this study reports a 
failure rate below 0.5% and informs published successful use in greater than 518 peer review 
papers (www.aardexgroup.com).  In this study, medication adherence will be viewed as a 
measure of functional status in the Wilson and Cleary model. 
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1.7.7.5 Medical Outcomes Study Short Form-36 (MOS SF-36)   
For this study, HRQOL will be measured by the physical component score (PCS) and mental 
component score (MCS) from the MOS SF-36 (See Appendix B).  This well-known and widely 
used instrument has established reliability and validity in various age groups and diseases.  It has 
a fair test-retest reliability with median r = 0.64 and good internal consistency with median alpha 
= 0.80 (McHorney, Ware, Lu, & Sherbourne, 1994; McHorney, Ware, & Raczek, 1993; 
McHorney, Ware, Rogers, Raczek, & Lu, 1992). 
The MOS SF-36 contains eight scales that measure health status.  They are physical 
functioning, role functioning-physical, role functioning-emotional, social functioning, bodily 
pain, mental health, vitality, and GHP.  The Vitality and GHP subscales were used as measures 
of symptom status and general health perceptions in the model, respectively.  The Mental 
HRQOL and Physical HRQOL are summary scales with possible scores range from 0 to 100, 
where 0 is the worst health status and 100 is the best health status (Ware, Kosinski, & Keller, 
1994).  The mental HRQOL is made up of all eight scores mostly derived from the mental 
health, role functioning-emotional, and social functioning scores.  The physical HRQOL is also 
made up of all eight scores primarily derived from the physical functioning, role functioning-
physical, and bodily pain scores.  The mental HRQOL and physical HRQOL component scores 
from the MOS SF-36 are highly ordinally scaled and approximate interval scaled variables.  
Mental HRQOL and physical HRQOL were considered measures of HRQOL in the model. 
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1.7.8 Procedures for Data Collection 
In the parent study, physicians in the clinic reviewed the study with their patients and asked 
permission for the clinic clinicians to meet with them.  If the potential subject agreed, the 
clinician presented the study and obtained permission to share their contact information with the 
principal investigator and project nurse.  If potential subjects agreed, the project nurse reviewed 
the medical record to evaluate eligibility and met with the potential subjects during a schedule 
clinic appointment. 
Those who agreed to participate provided written informed consent that covered the study 
description, purpose of the study, potential risks and benefits of participation, and subject rights 
(confidentiality, right to withdraw without risk or disruption of care).  At this time, those 
consenting were informed/encouraged to ask questions and given the PI’s contact information for 
future questions. 
Consenting subjects signed and dated three copies of the consent document, one for the 
research record, one for the medical record and one for the subject.  The principal investigator or 
project nurse witnessed the subject signing the consent document and signed and dated the 
consent document as well.  A log was maintained of potentially eligible subjects with the reasons 
for exclusion from the study. 
Subjects received the MEMS cap along with instructions on its use.  Subjects were 
directed to place the MEMS cap on the vial containing their ACE inhibitor medication.  They 
were informed to open the MEMS cap only to take the prescribed medication and to record on a 
medication diary the date, time, and reason for any other extra openings or missed doses over a 
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span of three months.  Those that used dose organizers were directed to place the MEMS fitted 
bottle next to their dose organizers and to open the cap on the bottle each time they removed the 
ACE inhibitor from their dose organizer. 
Subjects received a packet of baseline self-report questionnaires to complete and return 
within 2-3 days.  Time to complete the questionnaires was estimated at sixty minutes.  Subjects 
were given a pre-addressed stamped envelope to use for returning the completed questionnaires.  
The project nurse contacted subjects within three days after the clinic visit to follow-up on any 
additional questions and/or concerns related to the study.  MEMS data were collected over a 
three-month period.  At the end of three months, subjects returned the MEMS cap either at a 
follow-up clinic appointment or through the mail in a pre-addressed stamped envelope that the 
project nurse gave the subjects during the clinic visit and initial enrollment.  Final questionnaires 
were completed at the three-month follow-up clinic visits.  Medical records were reviewed to 
collect sociodemographic and medical data. 
After the three-month study, MEMS caps  were received and data were uploaded onto a 
project computer.  Event files were adjusted based on diary entries.  If the subject missed doses 
for hospitalization, the days of observation/monitoring were adjusted to reflect only those days 
not hospitalized.  If subjects opened the cap for reasons other than for taking medications, the 
event was deleted. 
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1.7.9 Procedures for Data Analysis 
1.7.9.1 Preliminary analysis 
Data screening and analysis to test the hypotheses will be performed using SPSS v 20.0 for 
Windows.  Frequency reports for all variables will be produced to determine if there are any 
inaccurate data or values that do not fall within the range expected.  The data will be summarized 
using frequencies, percentages, medians, means, ranges, and standard deviations as appropriate 
given the variable’s level of measurement and observed data distribution.  Measures of central 
tendency and dispersion of the variables will be explored.  Descriptive statistics will be used to 
examine demographic characteristics of the sample. 
Univariate and multivariate outliers  
Univariate and multivariate outliers will be assessed using frequencies, histograms, and 
scatter plots.  Z-scores will be computed to screen for univariate outliers.  Mahalanobis distance 
measures will be computed to screen for multivariate outliers. 
Normality 
Univariate normality will be assessed using frequencies, measures of skewness and 
kurtosis, histograms, and scatterplots.  Further normality will be assessed after fitting the model 
mainly by looking at residuals.  Data transformations will be considered including making the 
term quadratic, centering, and using a base 10 logarithm and analyses with comparison of both 
the transformed and nontransformed versions. 
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Linearity 
All terms will be evaluated for linearity using scatter plots and partial plots of residuals.  
If variables appear nonlinear, exploration of those variables with creation of variables to adjust 
for this (e.g., quadratic terms and centering) will occur to reduce the nonessential 
multicollinearity.  Multicollinearity screening will consist of examining conditioning indices and 
their corresponding variance decomposition proportions, tolerance, and variance inflation 
factors.  Homoscedasticity will be evaluated using bivariate scatter plots, partial plots, and 
residuals.  There are no missing data from the proposed study variables. 
1.7.9.2 Primary analysis for aim 1 
To test the first hypothesis that biological and physiological factors (EF and comorbid 
conditions), characteristics of the individual (age, gender, income, and prescription insurance), 
and characteristics of the environment (social support [4 variables] and medication regimen [2 
variables]) have a direct effect on symptom status (vitality), simple linear regression analysis will 
be conducted considering each predictor one at a time.  A standard multiple linear regression will 
be used for the analysis of the set of predictors of EF, comorbid conditions, age, gender, income, 
prescription insurance, social support, and medication regimen on vitality. 
1.7.9.3 Primary analysis for aim 2 
To test the second hypothesis that biological and physiological factors (EF and comorbid 
conditions), symptom status (vitality), characteristics of the individual (age, gender, income, and 
prescription insurance), characteristics of the environment (social support [4 variables] and 
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medication regimen [2 variables]) have a direct effect on medication adherence (3 variables), 
simple linear regression analysis will be conducted considering each predictor one at a time.  A 
standard multiple linear regression will be used for the analysis of the set of predictors of EF, 
comorbid conditions, vitality, age, gender, income, prescription insurance, social support, and 
medication regimen on medication adherence. 
1.7.9.4 Primary analysis for aim 3 
Simple linear regression taking each predictor one at a time will be utilized to analyze the third 
hypothesis that biological and physiological factors (EF and comorbid conditions), symptom 
status (vitality) characteristics of the individual (age, gender, income, and prescription 
insurance), characteristics of the environment (social support [4 variables] and medication 
regimen [2 variables]), and medication adherence (3 variables) have a direct effect on GHP.  
Multiple linear regression analysis will be used to examine joint associations between EF, 
comorbid conditions, vitality, age, gender, income, prescription insurance, social support, 
medication regimen, and medication adherence on GHP. 
1.7.9.5 Primary analysis for aim 4 
Simple linear regression taking each predictor one at a time will be utilized to analyze the fourth 
hypothesis that biological and physiological factors (EF and comorbid conditions), symptom 
status (vitality) characteristics of the individual (age, gender, income, and prescription 
insurance), characteristics of the environment (social support [4 variables] and medication 
regimen [2 variables]), medication adherence (3 variables), and GHP have a direct effect on 
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HRQOL (2 variables).  Multiple linear regression analysis will be used to examine joint 
associations between EF, comorbid conditions, vitality, age, gender, income, prescription 
insurance, social support, medication regimen, medication adherence, and GHP on HRQOL. 
1.7.9.6 Data interpretation 
Standard linear regression will be performed with forced variable entry, with point (regression 
coefficients) and interval estimates (95% confidence intervals) being obtained for each predictor 
variable.  Significance testing with the t-test at a significance level of .05 will be conducted to 
see if regression coefficients are different from zero.  For each model fitted, model summary 
statistics (adjusted R-square values and standard error of estimate) will be computed and a 
residual analysis using graphical and inferential methods will be conducted to assess for 
violations in the assumptions regarding the distribution of residuals (i.e., independence, linearity, 
homoscedasticity, and normality).  Data transformations will be considered if the distribution of 
residuals appears to be significantly skewed.  Scatterplots of each independent variable with the 
dependent variable will be viewed to verify that there is a linear relationship.  Residuals 
displayed in partial plots will also be visualized to view the direction and strength of the 
relationship and to check for outliers.  Transformations will be considered for outliers.  
Multicollinearity will be assessed by looking at the tolerance statistics, variance inflation factors, 
condition indices and variance decomposition proportions.  Screening for influential cases will 
also be accomplished.  Studentized deleted residuals and leverage statistics will be examined 
initially to identify potentially influential observations.  Change statistics (R-squared and F-test) 
will be examined in the regression analyses. 
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1.7.10 Study Limitations 
This proposed study is a secondary analysis of data, which is a limitation because the analyses 
are restricted to the data available in the parent study.  There will not be an opportunity to clarify 
or obtain additional data.  Data were not collected in the parent study with this research proposal 
as the focus, which may limit the appropriate information sought.  However, evaluation of the 
measures used in the parent study support their use to test the research hypotheses in this 
proposed study.  Errors in the original data collection will not be visible in this secondary 
analysis.  The descriptive correlational design of this study limits the ability to make causal 
inferences about the associations of the predictors on HRQOL. 
1.7.11 Potential Problems with Proposed Procedures 
The existing data were collected in 1998 and are dated.  However, HF continues to be a 
significant chronic disease and has not changed even in the past decade.  The rate of overall 
hospitalizations has not changed significantly from 2000 to 2010 and increases with age (Hall et 
al., 2012).  Therefore, the dataset is still relevant and appropriate for this secondary analysis of 
existing data.  This study is also limited as described in the parent study.  The parent study found 
that the rate of adherence was higher than the usual reports.  The authors surmised that higher 
adherence may be due to the study consisting of well-educated, married persons whose self-
reported household income was adequate for their needs (Bohachick et al. 2002). 
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1.7.12 Alternative Approaches to Achieve Specific Aims 
Alternative statistical software packages such as SAS could be used to evaluate the specific aims.  
The principal investigator will consult with the statistician member of the dissertation committee 
for evaluation of the appropriateness of the chosen methods of analysis utilizing the statistical 
software package of SPSS.  Input will be sought to determine if alternative approaches are 
warranted.  Should a change in approach be suggested, further consultation with the dissertation 
chair will occur.  Once all questions are answered and clarification sought, a collaborative 
decision will be made on whether or not to continue with the original research methods.  If an 
alternate approach is considered to be superior, efficient, and available, a new research plan will 
be drafted to guide this alternative approach. 
1.7.13 Plans for Further Testing 
Future research directions include examining mediation proposed in the Wilson and Cleary 
model.  This mediational analysis will likely include structural equation modeling, which is 
appropriate to examine mediation.  Through path analysis, the predictive and mediational roles 
of the variables described in the Wilson and Cleary model can be tested. 
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1.8 RESEARCH PARTICIPANT RISK AND PROTECTION 
A protocol application was submitted to the University of Pittsburgh Institutional Review Board 
(IRB) under exempt status (PRO10100156).  IRB approval for this secondary analysis of data 
was received on 02/07/2012.  See Appendix C for a copy of the IRB approval letter.  The 
principal investigator has obtained certificates of research training as required by the University 
of Pittsburgh (see Appendix D). 
1.8.1 Involvement of Human Participants 
This secondary analysis will consist of 161 subjects with age ranging from 21-82 years who were 
diagnosed with HF and prescribed ACE inhibitor therapy.  Subjects were also able to self-
manage their medications.  Subjects were excluded from the study if they had an unstable 
medical condition, exhibited signs of confusion, or were unable to read and write English.  There 
was not any involvement of vulnerable participants such as fetuses, pregnant women, children, or 
institutionalized individuals in this study. 
1.8.2 Sources of Data 
Patricia Bohachick, PhD, RN, principal investigator of the parent study, granted permission for 
Susan E. Simms, MSN, RN, CRRN, and PhD student at the University of Pittsburgh School of 
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Nursing to have access to the dataset to conduct the proposed secondary analysis of data.  The 
data are de-identified. 
1.8.3 Recruitment and Retention 
The study proposed is a secondary analysis of de-identified existing data.  No screening, 
recruitment, or follow-up will occur in the proposed research study.  The parent dataset reflects 
the gender and minority composition of the Pittsburgh area in which the HF clinic is located. 
1.8.4 Potential Risks 
There is minimal risk to the participants.  The data are already de-identified.  The likelihood of 
occurrence and seriousness of risk is null. 
1.8.5 Procedures to Minimize Potential Risks 
No protected health information will be accessed for this research or placed into the medical 
record.  No medical record data will be obtained.  No strategies to prevent breach of 
confidentiality are needed. 
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1.8.6 Cost-to-Benefit 
There will not be any compensation to subjects for participation in this research study.  Subjects 
will not receive a direct benefit from this research.  The knowledge gained may help to identify 
those factors contributing to the HF outcome of HRQOL, which in term may help the principal 
investigator to design interventions to improve HRQOL in this population. 
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2.0  MANUSCRIPT 1: PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE 
OF ADULTS WITH HEART FAILURE 
2.1 ABSTRACT 
Background: Heart failure patients experience low health-related quality of life and poor 
health outcomes. 
Objective: The purpose of this study was to examine interrelationships among and 
predictors of health-related quality of life of adults with heart failure. 
Methods: This cross-sectional secondary analysis of 161 older (M=56.09 years ± 11.74), 
white (93.2%), male (69.6%) heart failure patients was prescribed angiotensin converting 
enzyme inhibitors and used electronic Medication Event Monitoring System.  Ejection fraction, 
comorbid conditions, vitality, age, gender, income, prescription insurance, social support 
(appraisal, belonging, self-esteem, and tangible support by Interpersonal Support Evaluation 
List), medication regimen (number of prescribed medications and times per day medication is 
prescribed), medication adherence (days adherence and on-time adherence), general health 
perceptions, and health-related quality of life (Short Form-36 physical and mental component 
scores) were analyzed by simple and multiple linear regression. 
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Results: Vitality was positively associated with mental (p=<.001) and physical (p=<.001) 
component scores of health-related quality of life.  Females (p=.033) and those with prescription 
insurance (p=.032) had decreased mental component scores, while on-time adherence (p=.043) 
was positively associated with mental component scores.  Greater number of prescribed 
medications (p=.038) was associated with decreased physical component scores, while increased 
general health perceptions (p<.001) were associated with increased physical component scores.  
More comorbid conditions (p=.024) and increased social support (appraisal, p=.016) were 
associated with decreased vitality, whereas increased social support (self-esteem, p=.035) was 
associated with increased vitality.  Higher income (p=.023) was associated with increased days 
adherence.  Greater number of times per day medication is prescribed (p=.002) was associated 
with decreased on-time adherence, and higher ejection fraction (p=.032) was associated with 
increased on-time adherence.  Vitality (p<.001) was positively associated with general health 
perceptions. 
Conclusions: Interventions that incorporate these variables may reduce negative impacts 
on health-related quality of life and improve health outcomes in heart failure patients. 
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2.2 INTRODUCTION 
Heart failure (HF), a chronic disease in which the heart cannot pump enough blood to meet the 
body’s needs (Hall, Levant, & DeFrances, 2012), affects approximately 5.1 million adult 
Americans with 670,000 new cases per year (Lloyd-Jones et al., 2010).  Even with breakthroughs 
in treatment, HF remains a common diagnosis in hospital admissions and mortality.  HF 
accounted for 1,106,000 hospitalizations in 2006 and resulted in approximately 281,437 deaths 
in 2008 (Lloyd-Jones et al., 2010; Roger et al., 2012).  Approximately 50% of people diagnosed 
with HF will be deceased within five years (Levy et al., 2002).  HF is the most common 
diagnosis of hospitalized patients over 65 years and men (Lloyd-Jones et al., 2010; Roger et al., 
2004).  HF accounts for an estimated 40% of preventable hospitalizations of adults over 65 years 
with a cost estimated at $32 billion for 2013 (Heidenreich et al., 2011). 
Health-related quality of life (HRQOL) is greatly decreased in patients with HF (Juenger 
et al., 2002).  Further, HRQOL is low in hospitalized patients with HF (Chin & Goldman, 1998).  
Numerous factors have been identified in various studies as contributing to HRQOL, such as 
symptom status (Heo, Moser, Riegel, Hall, & Christman, 2005; Kethrong, Jirapaet, Jitpanya, & 
Sloan, 2008), functional status (Hauptman, 2008), and general health perceptions (GHP) (Heo et 
al., 2005; Kethrong et al., 2008).  In addition, variables potentially influencing these predictors of 
HRQOL consist of biological and physiological features (ejection fraction (EF) and comorbid 
conditions), individual characteristics (age, gender, income, and prescription insurance 
coverage), and environmental characteristics (social support and medication regimen (number of 
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prescribed medications and number of times per day medication is prescribed).  However, no 
single study to date has examined all of these identified factors in a model for HF patients. 
HF management is complex with no single intervention or self-care modality to optimize 
outcomes.  Therefore, identification and examination of factors influencing HRQOL and their 
associated factors will provide keys to target interventions to improve HF outcomes.  The Wilson 
and Cleary (1995) model of HRQOL is an ideal model to test these factors in patients with HF.  
The knowledge gained would contribute to the development of multifaceted interventions to 
improve the main influences on HRQOL of persons with HF. 
2.3 BACKGROUND 
Since the hallmark Framingham Heart Study (FHS), which set the framework of determining HF 
risk factors and treatment, researchers have been studying relationships and interventions to 
improve HF outcomes (Mehta & Khan, 2002).  The Olmsted County study, utilizing the FHS 
criteria, identified HF trends and survival (Roger et al., 2004).  In 1991, Studies of Left 
Ventricular Dysfunction (SOLVD) investigators determined the addition of enalapril, an 
angiotensin converting enzyme (ACE) inhibitor, with current HF treatment, significantly 
decreased mortality and hospitalizations for HF (SOLVD Investigators, 1991).  The benefit of 
ACE inhibitors, described as the most important advance in HF therapy in recent times (Baker, 
Konstam, Bottorff, & Pitt, 1994), has become the standard recommended medication treatment 
for reducing HF mortality and hospitalizations.  Medication adherence is essential to the success 
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of living with HF (Evangelista & Shinnick, 2008).  Long-term medication adherence is 
commonly lacking for those with chronic diseases (Dunbar-Jacob, Bohachick, Mortimer, 
Sereika, & Foley, 2003), and medication non-adherence is the primary reason of HF flares and 
hospital readmissions (Chin & Goldman, 1998; Hope, Wu, Young, & Murray, 2004), which may 
be a contributing factor to poorer HRQOL (Hauptman, 2008). 
In 2001, the Joint Commission and Centers for Medicare and Medicaid Services (CMS) 
identified HF diagnosis as one of the core measures to integrate performance measures with 
accreditation.  Hospitals are charged with identifying and providing standard evaluation and 
interventions for a variety of targeted procedures and diagnoses, including HF.  Performance 
measures of HF include discharge instructions, left ventricular function assessment, ACE 
inhibitor use for left ventricular systolic dysfunction, and adult smoking cessation 
advice/counseling.  The goal is to decrease the number of preventable readmissions by 
effectively treating and educating HF patients while they are in the hospital.  This initiative 
indicates that multiple factors influencing HF readmissions must be addressed.  Although there 
has been significant improvement in the successful management of HF with national initiatives, 
including decreasing mortality rates, there is no significant decrease in HF incidence (Roger et 
al., 2004). 
It is common for people with HF to experience exercise intolerance and fatigue 
symptoms (Lewis et al., 2007).  Better physical symptom status has been related to increased 
HRQOL and is a predictor of HRQOL (Heo et al., 2005; Kethrong et al., 2008).  Yet, there are 
limited studies in the literature on symptom status and HRQOL in persons with HF.  Symptom 
status, such as vitality (VT), in persons with HF is in need of further study. 
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Health perceptions are low in older patients with HF compared to healthy older adults 
(Carlson, Pozehl, Hertzog, Zimmerman, & Riegel, 2013; Heo, Moser, Lennie, Zambroski, & 
Chung, 2007).  Low health perceptions are linked to higher mortality in patients with HF.  Health 
perceptions have been identified as predictors of HRQOL in older adults with HF (Johansson, 
Brostrom, Dahlstrom, & Alehagen, 2007). 
There have been inconsistent findings in studies of biological and physiological factors 
on HRQOL in patients with HF.  EF has been identified as a predictor of HRQOL in one study 
(Lewis et al., 2007), but not in other studies (Clark, Tu, Weiner, & Murray, 2003; Heo, Doering, 
Widener, & Moser, 2008; Juenger et al., 2002; Kethrong et al., 2008).  Fewer comorbidities have 
been associated with increased HRQOL (Seto et al., 2011) while other studies have not found 
comorbidities to be influential (Clark et al., 2003; Heo et al., 2008).  These results warrant 
further evaluation of the effect of biological and physiological variables on HRQOL. 
Individual factors, such as age, gender, income, and prescription insurance coverage, 
have been associated with HRQOL.  Older age has been associated with lower HRQOL 
(Gallicchio, Hoffman, & Helzlsouer, 2007).  Low HRQOL has been reported by both men and 
women with HF (Gallicchio et al., 2007; Sayers, Riegel, Pawlowski, Coyne, & Samaha, 2008), 
but women to a greater extent (Bennett et al., 2001; Chin & Goldman, 1998; Gallicchio et al., 
2007).  Income and HRQOL have been linked in HF patients (Azevedo et al., 2008; Clark et al., 
2003).  The literature is lacking on relationships of prescription insurance with HRQOL, but 
insurance is often coupled with income in affording prescribed regimens for optimum outcomes. 
Environmental factors including social support and medication regimen have been related 
to HRQOL.  Positive social support has been identified as impacting HRQOL (Clark et al., 
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2003), while another study reported a negative direct effect (Kethrong et al., 2008).  Yet, another 
study found no impact at all (Heo et al., 2005).  Scant research is available on relationships 
between medication regimen and HRQOL.  Increased number of medications prescribed is 
associated with decreased HRQOL (Demir & Unsar, 2011). 
HF remains an extreme burden on the population as a whole (Roger et al., 2004).  Older 
adults lag behind in improvements in survival after the onset of HF compared to younger adults, 
which indicates that effective interventions tailored to increasing those factors that have a 
positive impact on HF management of older adults are needed.  Analysis of the gender 
differences in factors that affect HRQOL are lacking in the literature.  Social support has had 
varying degrees of meaning in the literature, so there is a need to clearly define and study the 
relationship of social support with HRQOL.  Income and prescription insurance coverage need 
further analysis as predictors of HRQOL.  Medication regimen needs further exploration to 
determine threshold and directional relationships with medication adherence and HRQOL.  
Given the lack of medication adherence in a large portion of the HF population, there is 
continued need for research on ways to improve medication adherence and HRQOL.  Research 
utilizing the components and influencing factors of the Wilson and Cleary (1995) model will 
contribute to a more complete understanding of the complexities and factors contributing to 
HRQOL in HF patients.  Efforts to improve HRQOL in HF patients could potentially decrease 
hospitalizations.  Interventions with even a small effect on hospital admissions could have a 
significant effect on the burden of cost of treatment of HF (Lee, Chavez, Baker, & Luce, 2004). 
Previous studies used the Wilson and Cleary (1995) model in HF patients (Arnold, 
Ranchor, Koeter, de Jongste, & Sanderman, 2005; Carlson et al., 2013); however, few studies 
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tested all of the domains and influencing factors of the Wilson and Cleary model (Heo et al., 
2005; Kethrong et al., 2008).  Krethong et al. (2008) tested the Wilson and Cleary model in 422 
HF clinic patients in Thailand.  Researchers collected medical record data and administered 
questionnaires.  They concluded each variable affected HRQOL with symptom status as most 
influential on HRQOL.  Patients who rated their functional status low also rated their GHP as 
low.  Heo et al. (2005) fully tested the Wilson and Cleary model including mediation by studying 
medical records of 293 HF patients who resided in the United States and were given the 
Minnesota Living with HF questionnaire.  Health perception and symptom status were 
determined to be most associated with HRQOL.  Future studies were recommended to fully 
validate the relationships among the variables in the Wilson and Cleary model.  Carlson et al. 
(2013) partially tested the Wilson and Cleary model focusing on overall perceived health as the 
outcome; environmental characteristics as predictors and HRQOL were not examined in this 
study.  This study was a secondary analysis of 265 subjects recruited for a study on the influence 
of excessive daytime sleepiness on self-care, HRQOL, and unplanned hospitalization.  
Significant findings were categorized into unmodifiable (black race, income, and comorbidity) 
and modifiable factors (symptom stability and social functioning in men only) as predictors of 
overall perceived health (Carlson et al., 2013).  Arnold et al. (2005) partially tested the Wilson 
and Cleary model comparing 95 chronic obstructive pulmonary disease (COPD) subjects with 90 
HF subjects.  The study investigated relationships between objective health parameters and 
general health perceptions mediated by symptoms of dyspnea and physical functioning.  
Individual and environmental characteristics and HRQOL were not studied.  Both COPD and HF 
patients perceived health competence was related to symptoms of dyspnea and GHP.  
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Additionally, symptoms of dyspnea were associated with self-reported physical functioning, 
which was related to GHP (Arnold et al., 2005). 
The Wilson and Cleary (1995) conceptual model being used in this study is comprised of 
five components: biological/physiological, symptom status, functional status, GHP, and overall 
quality of life with characteristics of the individual and the environment as influencing factors on 
the model.  Each of these components is proposed to be on a continuum from biological 
measures to more complex and integrated measures such as GHP and HRQOL.  The model 
proposes causal relationships with HRQOL as the final outcome. 
This study tested all of the components and influencing factors of the Wilson and Cleary 
(1995) model.  The biological/physiological component was operationalized as EF and comorbid 
conditions; symptom status was operationalized by a vitality scale; characteristics of the 
individual included age, gender, income, and prescription insurance; and characteristics of the 
environment included social support and medication regimen.  Functional status assesses the 
ability of the individual to perform a particular task and was operationalized as medication 
adherence.  The general health perceptions component was operationalized by a GHP scale.  
HRQOL was operationalized by scales of mental and physical health. 
2.3.1 Objective 
The purpose of the proposed study was to examine interrelationships among and predictors of 
HRQOL of adults with HF utilizing the Wilson and Cleary (1995) model (see Figure 3).  The 
specific aims were to examine (1) EF, comorbid conditions, age, gender, income, prescription 
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insurance, social support, and medication regimen as predictors of vitality; (2) EF, comorbid 
conditions, vitality, age, gender, income, prescription insurance, social support, and medication 
regimen as predictors of adherence to ACE inhibitor medication therapy; (3) EF, comorbid 
conditions, vitality, age, gender, income, prescription insurance, social support, medication 
regimen, and medication adherence as predictors of GHP; and (4) EF, comorbid conditions, 
vitality, age, gender, income, prescription insurance, social support, medication regimen, 
medication adherence, and GHP as predictors of HRQOL. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Study Model Based on Wilson and Cleary Model of Health-related Quality of Life 
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2.4 METHODS 
2.4.1 Design and Sample 
This study was a secondary analysis of cross-sectional data from the parent study, “Medication 
Adherence and Quality of Life in Chronic Illness” (National Institutes of Health, National 
Institute of Nursing Research, K01 NR00083, Principal Investigator: Patricia Bohachick).  This 
study used a descriptive correlational design to address the specific aims. 
The parent study convenience sample was comprised of HF clinic patients who attended 
the University of Pittsburgh Medical Center Heart Failure clinic in Pittsburgh, Pennsylvania.  
Participants had to be 21 years of age or older, prescribed ACE inhibitor therapy, and able to 
self-manage their medications.  Subjects were excluded from the study if they had an unstable 
medical condition, exhibited signs of confusion, or were unable to read and write English.  The 
subjects used electronic event medication monitoring by Medication Event Monitoring System 
(MEMS) over three months to evaluate adherence to ACE inhibitor therapy (Bohachick, Burke, 
Sereika, Murali, & Dunbar-Jacob, 2002). 
The initial sample in the parent study consisted of 235 subjects.  Sixty-four (27.2%) of 
those subjects used dose organizers where they removed multiple pills from the bottle with the 
MEMS cap and placed them into dose organizers from which to administer their medication.  
Since the parent study depended on the valid assessment of medication adherence, these 64 
subjects were excluded from the final sample in the parent study.  Thus, the final parent study 
sample was comprised of the 171 subjects who took their medication directly from the bottle 
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with the MEMS cap and completed the Interpersonal Support Evaluation List (ISEL), MOS SF-
36, and a demographics questionnaire. 
Data on 10 of the subjects in the final parent study sample had missing values on the 
predictors and outcomes examined in this study (one subject for number of times per day a 
medication is prescribed, seven subjects for income, and two subjects for prescription insurance 
coverage).  A missing values analysis demonstrated no variables with 5% or more missing 
values.  Chi Square analysis comparing the subjects in this study with no missing data (N=161) 
with those in the parent study (N=171) revealed no significant differences on gender, race, 
marital status, education level, income, insurance covering the cost of medication, EF, comorbid 
conditions, and medication regimen.  The t-test (t(169) = -2.669, p = .008) showed that there was 
a significant difference in mean age between the 161 subjects in this study with no missing data 
(M = 56.09, SD = 11.74 years) and the 10 subjects who had missing data (M = 45.90, SD = 
11.22 years).  The 161 subjects in this study were significantly older.  Given that the two samples 
were generally comparable, only differing on age, the 10 subjects with missing data were 
excluded from this study.  Thus, the sample for this study was comprised of 161 HF clinic 
patients with complete data on the study variables.  The current study was reviewed and 
approved by the University of Pittsburgh Institutional Review Board. 
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2.4.2 Measures 
2.4.2.1 Demographics questionnaire 
An investigator-developed demographics questionnaire was completed by subjects that provided 
data such as age, gender, marital status, race, education level, employment status, occupation, 
income, and questions about prescription insurance coverage and cost of medications.  Data from 
the demographics questionnaire were used to describe the sample.  Additionally, age, gender 
(male = 0, female = 1), income (less than $30,000 annually = 0, $30,000 and greater annually = 
1), and insurance data (no prescription insurance = 0, prescription insurance = 1) obtained from 
this form were utilized as characteristics of the individual in the model. 
2.4.2.2 Medical record data (MRD) 
Medical information was gathered from the subject’s medical record.  EF and comorbid 
conditions (less than 3 conditions = 0, 3 or more conditions = 1) were collected using MRD and 
were considered biological and physiological factors in the model.  Number of medications (less 
than 7 medications = 0, 7 or more medications = 1) and number of times per day medication is 
prescribed (less than 3 times = 0, 3 - 4 times = 1), both elements of the medication regimen and 
considered environmental characteristics in the model, were gathered using MRD. 
2.4.2.3 Interpersonal Support Evaluation List (ISEL) 
The ISEL, a 40-item self-report measure, was used to measure social support.  The ISEL is based 
on the premise that social resources potentially aid with coping in stressful situations.  The ISEL, 
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used to measure the perceived availability of potential social support resources, contains four 
subscales:  appraisal support, sense of belonging support, self-esteem support, and tangible 
support.  Appraisal support is one’s perceived availability to talk about one’s problems.  
Belonging support is the perceived availability of someone with whom one can do things.  Self-
esteem support is the perceived availability of a positive comparison of one’s self with others.  
Tangible support is perceived availability of material aid (Cohen, Mermelstein, Kamarck, & 
Hoberman, 1985).  The scores from the ISEL are highly ordinal and approximate interval scaled 
variables.  Half (20 items) of the items are constructed positively and half (20 items) negatively.  
Items are rated on a 4-point scale with response to statement choices of definitely false, probably 
false, probably true, or definitely true.  Each statement has a scoring range of 0 - 3 with a 
potential range of 0 - 120 for the total score.  The higher the score, the greater the perceived 
social support is viewed.  The subscale scores are obtained similarly with a range from 0 - 30 
with higher scores meaning greater perceived support (Cohen et al., 1985). 
The ISEL is a widely used valid and reliable instrument.  The general population scale 
correlated at 0.30 with the established Moos Family Environment Scale and 0.31 with the Partner 
Adjustment Scale (Cohen et al., 1985).  Cohen et al. (1985) reported that internal consistency 
reliability in the general population was favorable with alpha coefficient ranges for the total 
ISEL from 0.88 to 0.90.  Reports of the subscales were 0.70 to 0.82 for appraisal support, 0.73 to 
0.78 for belonging support, 0.62 to 0.73 for self-esteem support, and 0.73 to 0.81 for tangible 
support.  For this study, the total ISEL had an excellent alpha coefficient of .931.  For the 
subscales, there was good internal consistency reliability for appraisal (α = .883) and belonging 
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(α =.836) support, while self-esteem (α =.783) and tangible (α =.705) support demonstrated fair 
internal consistency reliability. 
Test-retest reliability was reported for two days, six weeks, and six months in the general 
population from data obtained from five studies.  Reliability estimates ranged from 0.70 to 0.87 
for the total score, 0.60 to 0.84 for appraisal support, 0.65 to 0.68 for belonging support, 0.54 to 
0.74 for self-esteem support, and 0.49 to 0.78 for tangible support (Cohen et al., 1985). 
The general population ISEL was administered three times in the Oregon Smoking Study 
(community sample) at baseline, six weeks, and six months.  Mean scores ranged from 32.9 to 
34.4.  Standard deviations ranged from 4.96 to 5.98.  In this analysis, social support was viewed 
as a characteristic of the environment in the model. 
2.4.2.4 Medication Event Monitoring System (MEMS) 
Medication adherence was measured by electronic event monitoring using MEMS.  This method 
provides a more objective method than the self-report method of medication adherence.  Data are 
stored electronically in the cap of the pill bottle that can later be downloaded for analysis of 
medication-taking practices. 
The MEMS recorded the date and time the bottle was opened.  From these serially 
collected data, summary indices were derived that provided global measures of medication 
adherence for the 3 months of monitoring that are continuous ratio scaled variables.  The three 
measures of medication adherence are: percentage of prescribed administrations taken (dose 
adherence), percentage of days with the prescribed number of administrations (days adherence), 
and percentage of days with the prescribed number of administrations and optimal inter-dose 
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intervals (on-time adherence).  The medication adherence variable, percentage of prescribed 
administrations taken, was removed from the analysis due to lack of variability.  Optimal inter-
dose intervals were computed as the time interval between bottle openings and were within 25% 
of the optimal dosing interval.  For example, for once daily dosing, 24 ± 6 hours of the previous 
bottle opening is optimum; for twice daily dosing, 12 ± 3 hours of the previous bottle opening is 
optimum; and for three times per day dosing, 8 ± 2 hours of the previous bottle opening is 
optimum. 
Obtaining adherence data electronically, such as through the MEMS, reveals adherence 
information that may not otherwise be obtained through alternate means such as via diary 
submission.  MEMS provides a consistent accuracy that varies with the self-report methods.  The 
AARDEX Group (n.d.) that manufactures the MEMS product used in this study reports a failure 
rate below 0.5% and informs published successful use in greater than 518 peer review papers 
(www.aardexgroup.com).  In this study, medication adherence was viewed as a measure of 
functional status in the model. 
2.4.2.5 Medical Outcomes Study (MOS) Short Form-36 (SF-36) 
HRQOL was measured by the mental component score (mental HRQOL) and physical 
component score (physical HRQOL) from the MOS SF-36.  This well-known and widely used 
instrument has established reliability and validity in various age groups and diseases.  It has fair 
test-retest reliability with median r = 0.64 and good internal consistency with median alpha = 
0.80 (McHorney, Ware, Lu, & Sherbourne, 1994; McHorney, Ware, & Raczek, 1993; 
McHorney, Ware, Rogers, Raczek, & Lu, 1992). 
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The MOS SF-36 contains eight scales that measure health status.  They are physical 
functioning, role functioning-physical, role functioning-emotional, social functioning, bodily 
pain, mental health, vitality, and GHP.  Vitality and GHP subscales were used as measures of 
symptom status and general health perceptions in the model, respectively.  The Mental HRQOL 
and Physical HRQOL are summary scales.  The mental HRQOL is made up of all eight scores 
mostly derived from the mental health, role functioning-emotional, and social functioning scores.  
The scores range from a possible 0 to 100, where 0 is the worst health status and 100 is the best 
health status (Ware, Kosinski, & Keller, 1994).  The physical HRQOL is also made up of all 
eight scores primarily derived from the physical functioning, role functioning-physical, and 
bodily pain scores.  The mental HRQOL and physical HRQOL component scores from the MOS 
SF-36 are highly ordinally scaled and approximate interval scaled variables.  Mental HRQOL 
and physical HRQOL were considered measures of HRQOL in the model. 
2.4.3 Procedures 
In the parent study, physicians in the clinic reviewed the parent study with their patients and 
asked permission for the clinic clinicians to meet with them.  If the potential subjects agreed, the 
clinician presented the study and obtained permission to share their contact information with the 
principal investigator and project nurse.  If potential subjects agreed, the project nurse reviewed 
their medical record to evaluate eligibility and met with the potential subjects during a schedule 
clinic appointment.  Those who agreed to participate provided written informed consent. 
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Subjects received the MEMS cap along with use instructions.  Subjects were directed to 
place the MEMS cap on the vial containing their ACE inhibitor.  They were informed to open the 
MEMS cap only to take the medication and to record on a medication diary the date, time, and 
reason for any other extra openings or missed doses over three months.  Those who used dose 
organizers were directed to place the MEMS fitted bottle next to their dose organizers and to 
open the cap on the bottle each time they removed the ACE inhibitor from their dose organizer. 
Subjects received a packet of baseline questionnaires to complete and return within 2 - 3 
days, estimated at 60 minutes to complete.  Subjects were given a pre-addressed stamped 
envelope to use for returning the completed questionnaires.  The project nurse contacted subjects 
within three days after the clinic visit to follow-up on any additional questions and/or concerns 
related to the study.  Final questionnaires were completed at three-month follow-up clinic visits.  
Medical records were reviewed to collect sociodemographic and medical data. 
MEMS data were collected over a three-month period, after which subjects returned the 
MEMS cap at a follow-up appointment or through the mail in a pre-addressed stamped envelope 
that the nurse gave the subjects during the initial enrollment.  MEMS data were then uploaded 
from the cap into a database on a project computer for processing.  Event files were adjusted 
based on diary entries (e.g., a bottle opened for refill was excluded).  If the subject missed doses 
for hospitalization, the days were refined to reflect only those days not hospitalized.  If subjects 
opened the cap for reasons other than for taking medications, the event was deleted. 
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2.4.4 Data Analysis 
Data screening and analysis to address the research aims were performed using SPSS v20.0 for 
Windows.  Frequency reports for all variables were produced to determine if there were any 
inaccurate data or values that did not fall within the range expected.  Univariate and multivariate 
outliers were assessed using frequencies, histograms, and scatter plots.  Normality was assessed 
using frequencies, measures of skewness and kurtosis, histograms, scatterplots, and residuals.  
The medication adherence variables were reflected then transformed using a base 10 logarithm 
and analyses were run comparing both the transformed and nontransformed versions.  Where the 
transformed versions were used, this affected the interpretation of results into a reflected form.  
All variables were evaluated for linearity.  If variables appeared nonlinear, exploration of those 
terms with creation of proper terms (e.g., quadratic terms and centering) occurred to reduce the 
nonessential multicollinearity.  The significance level was set at p < 0.05 for all analyses. 
EF was dichotomized into two categories with a cut point of 35% (EF less than 35% = 0, 
35% and greater = 1).  It has been found that patients with EF greater than 35% have a lower 
mortality rate and experience more adverse events (Quinones et al., 2000).  Results were 
generally similar between EF dichotomized using the cut point of 35% and EF reported as a 
percentage, with the exception that percentage of EF predicted days adherence in simple linear 
regression (β = -.194, p = .014) and multiple linear regression (β = -.321, p = .032).  Therefore, 
we reported the dichotomized version in the results. 
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2.4.4.1 Primary analysis for aim 1 
 
To test the first aim that biological and physiological factors (EF and comorbid conditions), 
characteristics of the individual (age, gender, income, and prescription insurance), and 
characteristics of the environment (social support [4 variables] and medication regimen [2 
variables]) have a direct effect on symptom status (vitality), simple linear regression analysis was 
conducted considering each predictor one at a time.  A standard multiple linear regression was 
used for the analysis of the set of predictors of EF, comorbid conditions, age, gender, income, 
prescription insurance, social support, and medication regimen on vitality. 
2.4.4.2 Primary analysis for aim 2 
The second aim tested if biological and physiological factors (EF and comorbid conditions), 
symptom status (vitality), characteristics of the individual (age, gender, income, and prescription 
insurance), characteristics of the environment (social support [4 variables] and medication 
regimen [2 variables]) have a direct effect on medication adherence (2 variables).  Days 
adherence had non-normality properties (skewness and kurtosis) so it was reflected and 
transformed using log10 to improve the residuals.  On-time adherence was also reflected and 
transformed to improve the residuals for linear regression.  The residuals improved with the 
transformed data.  Linear regression was performed on both the transformed and non-
transformed days adherence and on-time adherence dependent variable with each proposed 
predictor.  Simple linear regression analysis was conducted considering each predictor one at a 
time.  A standard multiple linear regression was used for the analysis of the set of predictors of 
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EF, comorbid conditions, vitality, age, gender, income, prescription insurance, social support, 
and medication regimen on medication adherence. 
2.4.4.3 Primary analysis for aim 3 
Simple linear regression taking each predictor one at a time was utilized to analyze the third aim 
that biological and physiological factors (EF and comorbid conditions), symptom status (vitality) 
characteristics of the individual (age, gender, income, and prescription insurance), characteristics 
of the environment (social support [4 variables] and medication regimen [2 variables]), and 
medication adherence (2 variables) have a direct effect on GHP.  Multiple linear regression 
analysis was used to examine joint associations between EF, comorbid conditions, vitality, age, 
gender, income, prescription insurance, social support, medication regimen, and medication 
adherence on GHP. 
2.4.4.4 Primary analysis for aim 4 
Simple linear regression taking each predictor one at a time will be utilized to analyze the fourth 
aim that biological and physiological factors (EF and comorbid conditions), symptom status 
(vitality) characteristics of the individual (age, gender, income, and prescription insurance), 
characteristics of the environment (social support [4 variables] and medication regimen [2 
variables]), medication adherence (2 variables), and GHP have a direct effect on HRQOL (2 
variables).  Multiple linear regression will be used to examine joint associations between EF, 
comorbid conditions, vitality, age, gender, income, prescription insurance, social support, 
medication regimen, medication adherence, and GHP on HRQOL. 
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2.5 RESULTS 
2.5.1 Sample Characteristics 
The sample (N = 161) was predominantly older (M = 56.09 ± 11.74 years, range 21 - 82), white 
(n = 150, 93.2%), married (n = 126, 78.3%), and with 12 years or greater education (n = 146, 
90.7%).  Forty nine (30.4%) were female.  Thirty-seven (23.0%) were employed either full or 
part time.  Eighty-one (50.3%) had an annual household income of $30,000 or more.  One 
hundred eleven (68.9%) had prescription insurance coverage.  EF ranged from 10% to 65% with 
a mean of 30.0% ± 11.0%.  EF of 35% or more was reported in 27.3% (n = 44) of the sample.  
The type of cardiomyopathy was mostly idiopathic (n = 97, 60.2%) and ischemic (n = 57, 
35.4%).  Comorbid conditions ranged from 0 to 7 with a mean of 2.52 ± 1.55; 80 (49.7%) 
subjects had 3 or more comorbidities.  The top five comorbid conditions were dysrhythmias (n = 
55, 34.2%), coronary artery disease (n = 48, 29.8%), hypertension (n = 46, 28.6%), diabetes (n = 
41, 25.5%), and myocardial infarction (n =37, 23%).  The number of medications prescribed 
ranged from 1 to 18 with a mean of 6.64 ± 2.94.  Almost half (n = 74, 46.0%) had seven or more 
medications prescribed.  The number of times per day medications is prescribed ranged from 1 to 
4 with a mean of 2.34 ± 0.77; 60 (37.3%) subjects took medications 3 to 4 times per day. 
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2.5.2 Predictors of Vitality 
Table 1 presents the results of simple linear regression and multiple linear regression to identify 
independent variables associated with Vitality.  Greater belonging support (β = .297, p = <.001), 
greater self-esteem support (β = .356, p = <.001), and greater tangible support (β = .311, p = 
<.001) were each significantly related to higher vitality.  Women (β = -.245, p = .002) and those 
with more comorbid conditions (β = -.255, p = .001) and more prescribed medications (β = -.198, 
p = .012) reported significantly lower vitality than men and those with fewer comorbid 
conditions and fewer prescribed medications.  In the multiple linear regression analysis, 
increased self-esteem support (β = .225, p = .035) was independently associated with increased 
vitality, while more comorbid conditions (β = -.206, p = .024) and increased appraisal support (β 
= -.266, p = .016) were significantly and independently associated with lower vitality with 27% 
of the variance explained (R2 = .272). 
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Table 1. Regression Analysis with Vitality 
Simple Linear Regression (SLR) and Multiple Linear Regression (MLR) Predicting Symptom 
Status: Vitality Measured from the Medical Outcomes Study (MOS) Short Form-36 (SF-36) (N = 
161) 
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2.5.3 Predictors of Medication Adherence 
Table 2 reports simple and multiple linear regression to identify predictors of days adherence.  
Each variable was examined individually as a predictor of days adherence.  Subjects with higher 
income (>$30,000 annually) had significantly increased days adherence (β = -.218, p = .005).  
Additionally, those with greater number of times per day medication is prescribed (3 or 4 
times/day) had significantly decreased days adherence (β = .204, p = .009).  In the multiple linear 
regression model, only higher income (β = -.192, p = .023) was identified as a significant 
independent predictor of increased days adherence (R2 = .109). 
In Table 3, the results of simple linear and multiple linear regression are shown for on-
time adherence.  Higher EF (β = -.189, p = .016) and higher income (β = -.187, p = .018), were 
each significant individual predictors of increased on-time adherence, while greater times/day 
medication is prescribed (β = .331, p < .001) was a significant individual predictor of decreased 
on-time adherence.  Multiple linear regression showed that increased EF (β = -.179, p = .032) 
was independently associated with increased on-time adherence, and greater number of times per 
day medication is prescribed (β = .270, p = .002) was independently associated with decreased 
on-time adherence (R2 = .181). 
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Table 2. Regression Analysis with Days Adherence 
Simple Linear Regression (SLR) and Multiple Linear Regression (MLR) Predicting Medication 
Adherence: Percentage of Days with the Prescribed Number of Administrations (Days 
Adherence) (N = 161) 
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Table 3. Regression Analysis with On-Time Adherence 
Simple Linear Regression (SLR) and Multiple Linear Regression (MLR) Predicting Medication 
Adherence: Optimal Inter-dose Intervals (On-Time Adherence) (N = 161) 
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2.5.4 Predictors of General Health Perceptions 
Refer to Table 4 for simple and multiple linear regression analyses for GHP.  In simple linear 
regression analysis, higher EF (β = .209, p = .008), increased vitality (β = .611, p < .001), 
increased belonging support (β = .197, p = .012), increased self-esteem support (β = .256, p = 
.001), and increased tangible support (β = .254, p = .001), were each individually associated with 
increased GHP, while greater comorbid conditions (β = -.302, p < .001) and greater number of 
prescribed medications (β = -.325, p < .001) were associated with decreased GHP.  In the 
multiple linear regression, increased vitality (β = .560, p < .001) was the only significant 
independent predictor of increased GHP (R2 = .459). 
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Table 4. Regression Analysis with General Health Perceptions (GHP) 
Simple Linear Regression (SLR) and Multiple Linear Regression (MLR) Predicting General 
Health Perceptions (GHP) (N = 161) 
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2.5.5 Predictors of HRQOL 
Table 5 contains the results of simple and multiple linear regression models for mental HRQOL.  
In simple linear regression, increased vitality (β = .573, p < .001), higher income (β = .209, p = 
.008), increased appraisal support (β = .249, p = .001), increased belonging support (β = .392, p 
< .001), increased self-esteem support (β = .441, p < .001), and increased tangible support (β = 
.308, p < .001) were each significantly associated with increased mental HRQOL.  Conversely, 
older age (β = -.222, p = .005) and women (β = -.241, p = .002) had significantly lower mental 
HRQOL than younger age and men.  In multiple linear regression, increased vitality (β = .482, p 
< .001) and increased on-time adherence (β = .182, p = .043) were significant independent 
predictors of increased mental HRQOL, whereas women (β = -.141, p = .033) and those with 
prescription insurance covering the cost of medication (β = -.144, p = .032) had significantly 
decreased mental HRQOL (R2 = .490). 
Table 6 shows the simple and multiple linear regression models of physical HRQOL.  
Higher EF (β = .185, p = .019), increased vitality (β = .687, p < .001), increased belonging 
support (β = .163, p = .039), increased self-esteem support (β = .271, p = .001), increased 
tangible support (β = .233, p = .003), and increased GHP (β = .697, p < .001) were each 
significantly related to increased physical HRQOL, while greater comorbid conditions (β = -
.396, p < .001) and fewer number of prescribed medications (β = -.393, p < .001) were each 
significantly related to decreased physical HRQOL.  In the multiple regression analysis, 
increased vitality (β = .389, p < .001), and increased GHP (β = .372, p < .001) were significant 
independent predictors of increased physical HRQOL, while greater number of prescribed 
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medications (β = -.142, p = .038) was a significant independent predictor of decreased physical 
HRQOL (R2 = .652). 
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Table 5. Regression Analysis with Mental Health-related Quality of Life (HRQOL) 
Simple Linear Regression (SLR) and Multiple Linear Regression (MLR) Analysis Predicting 
Health-Related Quality of Life Mental Component Score (Mental HRQOL) (N = 161) 
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Table 6. Regression Analysis with Physical Health-related Quality of Life (HRQOL) 
Simple Linear Regression (SLR) and Multiple Linear Regression (MLR) Predicting Health-
Related Quality of Life Physical Component Score (Physical HRQOL) (N = 161) 
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2.6 DISCUSSION 
This study of patients with HF in the United States further tested all of the domains and 
influencing factors in the Wilson and Cleary (1995) model.  This was the first study using the 
Wilson and Cleary model to measure mental and physical HRQOL with the SF-36.  The findings 
of this study supported some, but not all, of the proposed relationships. 
Comorbid conditions, female, belonging support, self-esteem support, tangible support 
and number of prescribed medications were individually related to vitality, while comorbid 
conditions, appraisal support, and self-esteem support were significant independent predictors of 
vitality in the multiple linear regression model.  This finding is consistent with Lerner and 
colleagues (1994) who studied 1,319 working men and women who completed a modified Job 
Content Questionnaire, a health distress scale, and the MOS SF-36 Health Survey to assess job 
strain and HRQOL in adults (Lerner, Levine, Malspeis, & D’Agostino, 1994).  In this study, two 
thirds of the subjects reported one or more chronic conditions.  The higher the number of chronic 
conditions, the association with all nine of the MOS subscales decreased (vitality included).  
General social support was also found to be an influence on vitality (Lerner et al., 1994).  In 
contrast, Heo et al. (2008) found that comorbid conditions and female were not predictors of 
physical symptom status.  Unlike this study, other studies have found that age was an important 
predictor of physical symptom status (Clark et al., 2003; Heo et al., 2005).  Perhaps the 
difference is due to the mean ages of the subjects in these studies being higher (63 and 73 years, 
respectively) compared to this study at 56.09 years, keeping in mind that the dropped subjects 
with some missing data were younger than the overall sample.  The number of medications and 
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its influence on vitality in HF patients has not been found in the literature.  However, 
nonadherence with the prescribed regimen can result in worsening symptoms (Van Der Wal, 
Jaarsma, & Van Veldhuisen, 2005). 
Comorbid conditions were not found to be associated with either days adherence or on-
time adherence, which is different than previous findings (Soumerai et al., 2006).  Higher EF 
was independently related to on-time adherence.  This result is not consistent with Kethrong and 
colleagues (2008) who concluded that EF had a negative direct effect on function in Thai HF 
subjects.  However, function was measured by the New York Heart Association functional 
classification.  Our study operationalized function by medication adherence.  Income emerged as 
a significant predictor of days adherence as well as on-time adherence.  Increased income was 
related to increased days adherence and on-time adherence.  Income has been ruled out as a 
factor on medication adherence in a previous study (Dunbar-Jacob et al., 2003).  The number of 
times per day medication is prescribed impacted both days and on-time adherence.  As the 
number of times per day medication is prescribed increased, the lower the days adherence and 
on-time adherence.  This finding is consistent with the literature that medication regimen 
complexity contributes to decreased adherence (Bohachick et al., 2002; Wu, Moser, Chung, & 
Lennie, 2008).  Additionally, Nieuwenhuis and colleagues (2012) specified that the number of 
doses per day and not the total number of prescribed medications affects adherence 
(Nieuwenhuis, Jaarsma, van Veldhuisen, & van der Wal, 2012). 
EF, vitality, belonging support, self-esteem support, and tangible support had positive 
associations with GHP.  Comorbid conditions and number of prescribed medications had 
negative associations with GHP.  EF findings are in contrast to other studies where EF was found 
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to have no significant association with GHP (Clark et al., 2003; Kethrong et al., 2008).  This 
result may be due to degree of EF in those HF subjects.  In both studies, most subjects had an EF 
greater than 40%, whereas in this study most subjects (72.7%) had an EF less than 35%.  Greater 
comorbid conditions were related to lower GHP in this study.  Again, this was in contrast to 
other studies that found comorbid conditions were not related to GHP (Clark et al., 2003; 
Kethrong et al., 2008).  The compositions of the subjects are also different.  One had a mean 
Charlson score of 3.68 (Clark et al., 2003) and Kethrong and colleagues (2008) reported 54.3% 
with no comorbid conditions.  This study had 49.7% with three or more comorbid conditions.  
Other studies had results similar to this study in which comorbid conditions were found to have 
negative associations with GHP (Lerner et al., 1994; Suwanno, Petpichetchian, Riegel, & 
Issaramalai, 2009).  The finding that vitality has a direct positive effect on GHP is consistent 
with other studies (Arnold et al., 2005; Carlson et al., 2013; Kethrong et al., 2008).  Belonging, 
self-esteem, and tangible social support were positively associated with GHP, which is consistent 
with other studies (Johansson et al., 2007; Kethrong et al., 2008; Lerner et al., 1994).  
Psychosocial function and breathlessness/physical function directly affect global perceived 
health (Johansson et al., 2007).  In Thai HF patients, social support had a significant positive 
direct effect on GHP while the number of prescribed medications had a direct negative 
relationship with GHP (Krethong et al., 2008).  The more medications prescribed, the lower the 
GHP reported.  Managing multiple medical prescriptive therapies has been associated with 
decreased overall perception of health (Carlson et al., 2013).  Age was found to have both 
positive (Clark et al., 2003) and negative (Suwanno et al., 2009) effects on overall perceived 
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health or health status.  This study found no significant relationship between age and GHP.  
These mixed findings warrant further testing and evaluation of these variables. 
The biological and physiological variables (EF and comorbid conditions) were associated 
with physical HRQOL.  Higher EF was associated with increased physical HRQOL and more 
comorbid conditions were associated with decreased physical HRQOL.  These findings are 
unique.  Other studies found no relationship between the biological and physiological variables 
and HRQOL (Clark et al., 2003; Heo et al., 2005; Juenger et al., 2002).  Symptom status 
(vitality) was significantly associated with mental and physical HRQOL in both simple and 
multiple linear regression analyses.  This result is not unique as other studies have shown that 
physical symptom status is not only a predictor, but a strong predictor of HRQOL (Heo et al., 
2005; Heo et. el., 2008; Kethrong et al., 2008).  Age was significantly related to mental HRQOL, 
which has been reported in previous studies (Clark et al., 2003; Heo et al., 2005).  Female had a 
negative association with mental HRQOL in our study, but Heo reported gender had no 
significant effect on HRQOL (Heo et al., 2005).  The social support variables had individual, 
significant, positive relationships with HRQOL (appraisal, belonging, self-esteem, and tangible 
support with mental HRQOL; belonging, self-esteem, and tangible support with physical 
HRQOL).  In contrast, increased social support was related to a decrease in HRQOL in Thai HF 
patients (Kethrong et al., 2008), whereas Heo et al. (2005) found no relation with social support 
in community hospital HF patients.  Income had a direct positive effect on mental HRQOL.  
These findings are consistent with the literature that increased socioeconomic status or greater 
income was related positively to HRQOL (Azevedo et al., 2008; Clark et al., 2003).  Insurance 
covering the cost of medication had an independent negative association with mental HRQOL.  
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This result suggests that having insurance that covers the cost of medication is associated with 
lower mental HRQOL, which seems counter-intuitive.  The literature is lacking information on 
relationships of prescription insurance with HRQOL.  In an attempt to explain this finding, a 
correlational analysis was run between prescription insurance coverage and the other variables in 
this study.  Older age (r = -.299, p = <.001) and being employed full or part time (r = -.272, p = 
<.001) were significantly correlated with lack of prescription insurance coverage.  Having 
prescription insurance coverage may explain more variance in mental HRQOL than variables 
related to prescription insurance, specifically age and employment status.  Also, it may be that 
prescription insurance coverage related to disability insurance is predictive of decreased mental 
HRQOL.  The number of prescribed medications has an independent negative effect on physical 
HRQOL.  As number of prescribed medications increased, HRQOL decreased, which others 
have reported (Demir & Unsar, 2011).  On-time adherence was independently related to mental 
HRQOL.  Hauptman (2008) determined that medication adherence may be a contributing factor 
to HRQOL.  GHP were also independently associated with physical HRQOL.  This finding is 
consistent with other studies that found that GHP had a strong association with HRQOL (Heo at 
al., 2005). 
2.6.1 Limitations 
This study was a secondary analysis of existing data, which did not allow the researchers to 
identify other variables for the model.  Data were not collected in the parent study with this 
research proposal as the focus, which limited the information sought.  However, evaluation of 
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the measures used in the parent study supported their use to test the aims in this study.  Errors in 
the original data collection were not visible in this secondary analysis.  The descriptive 
correlational design limits the ability to make causal inferences about the effects of the predictors 
on HRQOL.  The sample size adjustment was also a limitation since utilizing the subjects with 
only completed data resulted in a significantly older sample than the parent study.  Thus, the 
findings are generalizable to only an older HF population.  GHP, vitality, and HRQOL (mental 
and physical) were measured from the MOS SF-36 rather than independent measures.  This 
study examined unidirectional relationships in the Wilson and Cleary (1995) model.  Wilson and 
Cleary noted that the relationships could be considered in a bi-directional fashion. 
2.7 CONCLUSIONS AND IMPLICATIONS 
In summary, both mental and physical HRQOL were associated with most of the model 
predictors.  Vitality, belonging support, self-esteem support, and tangible support were 
associated with both mental and physical HRQOL.  Age, female, income, prescription insurance, 
appraisal support, and on-time adherence were associated with mental HRQOL.  EF, comorbid 
conditions, number of prescribed medications, and GHP were associated with physical HRQOL.  
Comorbid conditions, female, appraisal support, belonging support, self-esteem support, tangible 
support, and number of prescribed medications were related to vitality.  Income and number of 
times per day medication is prescribed were associated with both days and on-time adherence.  
EF was associated with on-time adherence.  GHP were affected by EF, comorbid conditions, 
 90 
 
 
vitality, belonging support, self-esteem support, tangible support, and number of prescribed 
medications. 
This study tested all of the domains and influencing factors from the Wilson and Cleary 
(1995) model with HF patients.  The findings supported some of the proposed relationships as 
described above.  This study confirms the multiple complexities of the important factors that 
influence HRQOL.  Incorporating the associated variables to develop multifaceted interventions 
may reduce negative impacts on HRQOL and health outcomes in HF. 
Future research directions include examining mediation proposed in the Wilson and 
Cleary model.  This mediational analysis will likely include structural equation modeling, which 
is appropriate for examining mediation.  Through path analysis, the predictive and mediational 
roles of the variables described in the Wilson and Cleary model can be tested. 
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